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Abstract  49 
Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) 50 
and the risk of major adverse cardiovascular events (MACE). However, large intervention 51 
trials on PR-tailored treatments have been neutral. The role and usefulness of PR with 52 
regard to levels of cardiovascular risk are unclear. We undertook a systematic review and 53 
meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes 54 
(ACS), ischemic strokes, and vascular deaths) in relation to PR and its interaction with 55 
cardiovascular risk levels. PR was determined using ADP-induced light transmission 56 
aggregometry with a primary concentration of 20µM ADP.Thirteen prospective studies 57 
totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5%) during a 58 
median follow-up of 12 months. The strength of the association between the risk of MACE 59 
and PR increased significantly (p=0.04) with the number of risk factors present (age>75 60 
years, ACS at inclusion, diabetes, and hypertension). No association was detected in 61 
patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was 62 
associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk 63 
factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-64 
PR: HR=3.7, p=0.0003). PR allowed the reclassification of 44% of the total population to a 65 
different risk level for the outcome of MACE, mostly in intermediate or high risk patients. 66 
 In conclusion, the magnitude of the association between PR and MACE risk is strongly 67 
dependent on the level of cardiovascular risk faced by patients on clopidogrel. 68 
 69 
Keywords: clopidogrel, drug response, platelets, cardiovascular diseases, ischemic events. 70 
 71 
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Introduction 73 
Atherosclerotic diseases account for more than 40% of deaths in Western countries, and 74 
antiplatelet therapy is a major preventive strategy in this setting(1). Clopidogrel, a P2Y12 75 
receptor blocker, inhibits the activation of platelets by adenosine diphosphate (ADP), and is 76 
widely prescribed for secondary prevention in patients with atherosclerotic diseases. When 77 
combined with aspirin, clopidogrel is particularly effective in patients with acute coronary 78 
syndromes (ACS)(2), and has proved superior to aspirin alone in several other large 79 
randomised controlled trials. The pharmacodynamic response to clopidogrel shows a wide 80 
inter-individual variability(3, 4). Numerous cohort studies, often performed on patients with 81 
acute coronary syndrome (ACS) and/or undergoing percutaneous coronary interventions 82 
(PCI), have shown an association between high on-treatment platelet reactivity (PR) and the 83 
risk of recurrent major adverse cardiovascular events (MACE)(5-7). However, recent studies 84 
in cohorts of stable cardiovascular outpatients(8, 9) or in medically managed ACS 85 
patients(10) failed to confirm these results. Several randomized trials aimed at reducing the 86 
recurrence of ischemic events have compared standard clopidogrel treatment to a P2Y12-87 
inhibitor strategy tailored according to the presence of high PR. Although initial small trials 88 
were promising(11, 12) more recent larger trials showed no benefit from adjusting clopidogrel 89 
doses or switching to prasugrel based on PR testing in low-risk coronary patients undergoing 90 
PCI(13, 14). These contrasting results, both from observational studies and randomized 91 
intervention trials, may be explained by different patient characteristics including the level of 92 
risk, but to date few data substantiate these hypotheses. We previously showed, in a study-93 
level meta-analysis, that the risk of recurrent MACE associated with high PR was greater in 94 
studies using GpIIb/IIIa inhibitors (a marker of high-risk patients) than in studies which did 95 
not(7). Another meta-regression from a study-level meta-analysis of randomized trials 96 
suggested that the higher the incidence of coronary stent thrombosis in a given study, the 97 
larger the net clinical benefit from a PR-tailored strategy(15). Finally, the ADAPT-DES 98 
registry of patients undergoing PCI showed that high PR was predictive of stent thrombosis 99 
mostly in ACS patients, but there was no interaction reported between PR and the presence 100 
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of an ACS at inclusion(16). This information suggests the hypothesis that high PR might be 101 
more relevant in high-risk populations, but convincing data at the individual level are lacking. 102 
To date, the only meta-analysis on individual patient data performed on 6 studies totaling 103 
3,059 patients assessed with the VerifyNow P2Y12 assay did not explore this hypothesis(17). 104 
Similarly, one of the largest and more recent meta-analysis on 8 studies and 4817 patients 105 
did not explore this interaction due to the lack of individual data(18). To further investigate 106 
this interaction on a larger population we performed a collaborative meta-analysis of 107 
individual patient data and focused on the interaction between relevant vascular risk factors 108 
and PR, assessed with ADP induced light transmission aggregometry (LTA), in order to 109 
better define the risk of MACE.  ADP-induced LTA is the assay upon which all P2Y12 receptor 110 
inhibitors have been developed, thus supporting its use in the present meta-analysis. In 111 
addition, among several available assays to evaluate PR, LTA is the historical gold standard 112 
with which most platelet function assays were compared.   113 
  114 
Page 5 of 127 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
Methods 115 
Data sources 116 
Literature review, confined to articles in English(19), was based on electronic databases 117 
(Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials) and 118 
abstracts from major international meetings held from 2010–2013 (ISTH, AHA, ACC, ESC). 119 
A free-text search was conducted using an ‘ADP’ and ‘aggregation’ and ‘clopidogrel’ key-120 
word combination. Articles were selected on the basis of abstracts, before examination of the 121 
full text. Reference lists of selected articles were also hand-searched to identify additional 122 
relevant reports. Reviewers (JLR and PF) were not blinded to the journal, authors or 123 
institutions in the publications as this has been shown to be unnecessary(20). The electronic 124 
database search was last updated on 31 July, 2013. The objective of this individual patients’ 125 
data meta-analysis was described in a project that was part of French ministry of health’s 126 
initiative to encourage meta-analyses (PHRC 15-07 to JL Reny “Etudes prospectives sur la 127 
réponse biologique au clopidogrel et évènements ischémiques chez les patients 128 
athérothrombotiques : Métaanalyse sur données individuelles et résumées” http://www.plan-129 
alzheimer.gouv.fr/IMG/pdf/Liste_des_dossiers_retenus_-_2_mai_2008.pdf ). Protocol in 130 
French available upon request.    131 
 132 
Study selection 133 
Selected studies met the following criteria: (a) patients were treated with clopidogrel and had 134 
symptomatic atherothrombosis (clinical signs related to vascular atherothrombotic lesions); 135 
(b) pharmacodynamic response to clopidogrel was evaluated using the maximal aggregation 136 
value from LTA on platelet-rich plasma with 20, 10, or 5 µM ADP as an agonist; (c) LTA was 137 
performed remote from platelet function interfering drugs such as GpIIb/IIIa inhibitors; (d) 138 
patients were prospectively monitored for MACE for at least 30 days, defined using at least 139 
one of the following items: acute coronary syndrome (unstable angina, myocardial infarction 140 
with/without ST segment elevation), ischemic stroke (acute neurological deficit due to a 141 
cerebral infarction), and vascular death; (e) studies involved either a prospective cohort or a 142 
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randomised therapeutic trial, but one in which treatment was allocated independently of the 143 
response to clopidogrel. When studies were suspected of including the same patients, the 144 
authors were asked to provide data from the largest possible number of independent patients.  145 
 146 
Data extraction 147 
The corresponding authors or principal investigators of eligible studies were contacted and 148 
asked to participate in the CLOpidogrel and Vascular ISchemic events – Individual Patient 149 
Data (CLOVIS-IPD) meta-analysis group. Investigators provided individual data on: the 150 
qualifying cardiovascular condition and clinical setting at inclusion (ACS or stable disease); 151 
MACE and date of occurrence during follow-up; platelet reactivity (PR) with ADP 20, 10, 152 
and/or 5 µM and its timing elative to loading dose of clopidogrel; age, gender, height, and 153 
weight; current smoking status, diabetes, hypercholesterolemia, and hypertension; left 154 
ventricular ejection fraction; platelet count; PCI; use of GpIIb/IIIa inhibitors and timing; 155 
concomitant medications; and bleeding events and timing during follow-up. Data were 156 
checked for completeness and consistency with published reports. Any discrepancies were 157 
resolved with the corresponding authors. After format harmonization, data were compiled for 158 
statistical analysis. All studies were approved by their respective institutional review boards.  159 
 160 
Quality assessment of studies  161 
A new quality assessment tool for prognostic studies called PROBAST (see 162 
Acknowledgements) was used to estimate risks of bias and concerns about applicability. As 163 
PROBAST is not customized for meta-analyses of individual patient data, items were 164 
adapted accordingly. Based on the present study’s list of relevant criteria, risks of bias, and 165 
concerns about applicability are rated as low, unclear, or high. Supplemental Figure 1 shows 166 
the list of criteria. 167 
 168 
Primary outcomes and measures 169 
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The primary clinical outcome was the occurrence of MACE, as defined above (see Study 170 
selection (d)). The primary biological outcome was maximal aggregation with 20 µM ADP, as 171 
it is a better concentration for analyzing the effects of clopidogrel than lower ones. PR was 172 
categorized in three strata. The higher cut-offs were selected on the basis of previously 173 
published cut-offs (59% to 64% for 20 µM ADP, and 43% to 46% for 5 µM ADP)(21), and to 174 
keep relatively balanced numbers of patients in each PR categories. Three pre-specified 175 
categories allowed a better description of the dose-dependent effects of PR on the risk of 176 
MACE compared to the usual dichotomous high and low PR categorization. Three categories 177 
were also chosen to better parallel the analysis with a therapeutic PR window that has been 178 
associated with optimal net clinical benefit(22).  A surrogate for the level of cardiovascular 179 
risk was defined as the number of factors with homogeneous definitions across studies, and 180 
these were markers of MACE in the meta-analysis. The factors were selected from among 181 
age, diabetes, hypertension, smoking, hypercholesterolemia, and the presence of an ACS at 182 
inclusion (as defined in study selection (d)), and were all provided at the time of inclusion and 183 
PR testing.  184 
 185 
Statistical analysis  186 
MACE-free survival curves were derived from individual patient data using the Kaplan-Meier 187 
estimator; curves were compared using log-rank tests stratified by study. Associations 188 
between conventional risk factors, PR strata, and risk of MACE were analyzed using 189 
multivariate, mixed-effect Cox models. The amount of heterogeneity was assessed by the 190 
size of the random effects (Tau2) which is an estimate of the between study variability(23). 191 
The presence of heterogeneity was tested by comparing models with and without random 192 
effects (likelihood ratio test). The interactions between the level of risk and PR strata were 193 
tested. MACE-free survival according to PR, as a continuous variable, was assessed using 194 
the R package prodlim using the symmetrical nearest neighborhoods method.(24) Sensitivity 195 
analyses were conducted to check the robustness of the findings with respect to: the risks of 196 
bias and concerns about the applicability of studies; the definition of MACE, including target 197 
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8 
vessel revascularization or PCI at inclusion, and; the influence of a given specific study. The 198 
net reclassification index (NRI) for survival data(25) was computed to quantify the 199 
contribution of PR testing for the prediction of the 6-month risk of MACE in patients with 200 
increasing numbers of traditional risk factors. The event and non-event continuous NRIs 201 
were reported. Potential publication bias was checked for. P-values below 0.05 were 202 
considered significant and all tests were two-sided. Published guidelines for meta-analysis of 203 
observational studies in epidemiology (MOOSE) and their reporting(26) were followed. 204 
Details on statistical methods are given in the online data supplement.  205 
 206 
Results 207 
Characteristics of included studies 208 
The Figure 1 flow-chart details how 13 of 20 qualifying studies were included, totaling 6,478 209 
patients(8, 27-38). Table 1 shows their characteristics. Data on body mass index, 210 
concomitant medications, left ventricular ejection fraction, or the occurrence of target and 211 
non-target vessel revascularization during follow-up were only available in some studies. All 212 
studies provided individual data allowing a homogeneous definition of MACE, current 213 
smoking status, ACS, diabetes (fasting plasma glucose ≥ 7.0 mmol/l, 2-h plasma glucose ≥ 214 
11.1 mmol/l after 75g oral glucose load or background therapy for diabetes), and 215 
hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or 216 
a documented history of hypertension). Hypercholesterolemia was not defined in a 217 
homogeneous fashion across studies and plasma LDL-cholesterol levels were not available 218 
for more than 2,000 patients. Overall, risks of bias and concerns about applicability were low 219 
(online data supplement further details study characteristics, bias, and applicability). 220 
Information on bleeding was limited to five studies, with only 67 major and 20 221 
moderate/minor bleedings.  222 
 223 
MACE and level of risk  224 
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Overall, 421 MACE occurred in 6,478 patients (6.5%), the majority being ACS (n = 383). 225 
There were 83 stent thromboses, including 79 definite or probable and four possible ones, all 226 
included in the composite outcome of MACE.  The MACE-free survival rate across the 227 
different studies at the end of follow-up ranged from 77.4% to 97.3%. In a multivariate 228 
analysis, four factors were found relevant to determining patients’ levels of risk: age greater 229 
than 75 years, diabetes, ACS at inclusion, and hypertension (Table 2). The number of these 230 
factors was used as a surrogate for the individual risk of MACE. Patients with none of these 231 
factors were classified ‘low-risk’, patients with one factor ‘intermediate-risk’, and patients with 232 
two or more factors ‘high-risk’ (global p-value <0.0001 for the trend). 233 
 234 
MACE and PR  235 
Nine studies (n = 4,438 patients) performed LTA using 20 µM ADP, four studies (n = 2,144 236 
patients) used 10 µM ADP, and eight studies (n = 3,317 patients) used 5 µM ADP. Figure 2 237 
shows the MACE-free survival curves by category of ADP concentration. Risk of MACE 238 
increased significantly with PR with 20 µM ADP, 10 µM ADP, and 5 µM ADP.  239 
With adjustment, high PR was still significantly associated with an increased risk of MACE 240 
(Table 3). However, for PR evaluated using 10 µM ADP, risk only increased for the highest 241 
PR category, corresponding to LTA values greater than 60%.  242 
 243 
Interaction between risk level and PR for the outcome of MACE 244 
 245 
Platelet reactivity assessed with 20 µM ADP. Patients with none of the four risk factors 246 
showed no significantly increased risk associated with PR, while for patients with one risk 247 
factor only, the higher strata of PR was associated with an increased risk of MACE. Patients 248 
with two or more risk factors showed an increased risk of MACE for both the medium and 249 
higher strata of PR. (Figure 3). In a Cox model, the interaction between PR strata and the 250 
risk level was statistically significant (p=0.04). The corresponding hazard ratios (HRs) are 251 
shown in Figure 3. Heterogeneity was not detected for the overall interaction (p=0.81), as 252 
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10 
well as when it was restricted to each risk level category (intermediate versus low risk level, 253 
p=0.45, and high versus low risk level, p=0.90). Additional results on heterogeneity are 254 
provided in the supplemental material. Figure 4A shows that PR, when analyzed in a 255 
continuous fashion, barely affects the risk of MACE at 6 months in patients with no risk 256 
factors:  the risk is close to 2% at six months, irrespective of the level of platelet reactivity. 257 
Conversely, patients with one risk factor and an overall 4.1% risk of MACE at six months 258 
have in fact a 2% risk of MACE when they have a low PR, or a 6% risk of MACE when they 259 
have a high PR (Figure 4B). Similarly, patients with two or more risk factors and an overall 260 
6% risk of MACE at six months can indeed have a 2% risk of MACE when they have a low 261 
PR (Figure 4C). The reclassification of the 6-month risk of MACE, according to the three 262 
categories of platelet reactivity, in patients with no, one and two or more risk factors, is 263 
shown in Table 4. Overall, PR allowed the reclassification of 44% of the total population 264 
(1837/4193 patients) included in a 6-month follow-up to a different level, mostly in patients 265 
originally identified as intermediate or high risk on the basis of the number of risk factors only. 266 
In patients experiencing MACE in the first 6 months of follow-up, the risk predicted by the 267 
combination of PR and risk factors was on average increased compared with the risk 268 
predicted from risk factors only: the continuous event net reclassification index (NRI) was 269 
0.39 (95%CI 0.23 to 0.62). Conversely, in patients free of MACE at 6 months, the measure of 270 
PR did not modify the predicted risk: the continuous non-event NRI was 0.01 (95%CI -0.16 to 271 
0.09). The overall NRI was 0.39 (95%CI 0.22 to 0.57). 272 
 273 
Platelet reactivity assessed with 10 µM ADP. A total of only five low-risk patients in four 274 
studies performing 10 µM ADP LTA to assess PR precluded an analysis of this low-risk 275 
group. Furthermore, the surrogate for risk level failed to demonstrate an association with the 276 
observed risk of MACE in these studies. Figure 4B shows that the risk of MACE increased in 277 
both intermediate- and high-risk patients for PR values above 40%, without any obvious 278 
relation with the level of risk.  279 
 280 
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Platelet reactivity assessed with 5 µM ADP. The direction of interaction between PR using 5 281 
µM ADP and the risk level was similar to that observed for PR using 20 µM ADP, even 282 
though overall interaction did not reach the significance level (p=0.17). Of note there were 283 
980 fewer patients in the studies performing 5 µM ADP than in those using 20 µM ADP. The 284 
increased risk of MACE as PR increases is indeed similar for intermediate- and high-risk 285 
patients; for low-risk patients PR is not associated with a MACE outcome (online data 286 
supplement). Heterogeneity was not detected for the overall interaction (p=0.19). Figure 4C 287 
shows that the risk of MACE was unaffected by PR in low-risk patients while it increased for 288 
PR values above 30% in intermediate-risk patients and for PR values above 10%–20% in 289 
high-risk patients. 290 
 291 
Sensitivity analyses 292 
Sensitivity analyses were performed for PR using 20 µM ADP to assess: the robustness of 293 
the association between PR and risk of MACE and its interaction with the level of 294 
cardiovascular risk; the robustness of the results in the population of PCI patients and when 295 
target vessel revascularization is added to the composite outcome. All analyses showed that 296 
the sizes of the effects remained similar, and whilst in some instances the statistical 297 
significance of the interactions could be lost, there was no impact on their magnitudes 298 
(supplemental Tables 1 and 2). Notably, when PR was categorized in quartiles (20 µM ADP 299 
maximal aggregation quartiles = 0%–38.1%, 38.2%–51.3%. 51.4%–63.0%, 63.1%–100%) 300 
the interaction between PR and the number of risk factors remained significant (p=0.01). 301 
When restricted to the population of 3,564 patients treated with PCI and tested using 20 µM 302 
ADP the interaction was of similar magnitude but no longer significant (supplemental Table 303 
3). 304 
 305 
Publication and availability biases 306 
A check for potential publication bias was made for PR using 20 µM ADP, on which the main 307 
analyses were performed. A funnel plot was obtained by representing the HR of PR using 20 308 
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µM ADP and the standard error, assessed in each separate study (supplemental Figure 4). 309 
Two studies with a negative association between PR using 20 µM ADP and the risk of MACE 310 
(with small sample sizes) were detected as missing using the ‘trim and fill’ method for making 311 
the funnel plot symmetrical. When these missing studies were added, the pooled HR was not 312 
significantly modified. These findings suggested that the publication bias in our meta-analysis 313 
was minor.  314 
Seven qualifying studies could not provide individual patient data. It is of note that in five of 315 
these, the relation between clopidogrel non-response and ischemic events was not a study 316 
objective (pharmacokinetic-pharmacodynamic studies or randomized trials of different 317 
clopidogrel loading doses). The two remaining studies (n = 101 and 111 patients) were 318 
specifically interested in the prognostic value of PR for MACE.  319 
  320 
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Discussion 321 
In the present meta-analysis of individual patient data conducted in a representative panel of 322 
clopidogrel-treated patients we demonstrated that the association between PR and the risk of 323 
MACE depended strongly on the level of cardiovascular risk. When using 20 µM ADP, the 324 
most commonly used concentration in LTA, the risk of MACE associated with PR increased 325 
with the level of cardiovascular risk. Indeed, PR did not affect the risk of MACE in patients 326 
presenting no risk factors, however it gradually increased the risk of MACE as the number of 327 
cardiovascular risk factors increased, reaching a 3.7 times greater risk in high-risk patients 328 
with a high PR. The measure of PR with 20 µM ADP, in addition to risk factors, modified the 329 
interpretation of the 6-month risk of MACE in 44% of patients, mainly in patients with at least 330 
one risk factor. 331 
Interestingly, smoking and hypercholesterolemia were not associated with the outcome of 332 
MACE and were not included in the analysis of the interaction between PR and risk factors. 333 
In randomized controlled trials, the ben fit of clopidogrel in reducing the incidence of MACE 334 
is primarily seen in smokers, with little benefit to non-smokers(39). With regard to the cohort 335 
studies of clopidogrel-treated patients included in this meta-analysis, this differential effect 336 
suggests that the increased risk of MACE related to smoking is offset by the benefit 337 
clopidogrel provides to smokers; it thereby weakens any possible analysis of the interaction 338 
between smoking and PR for outcomes of MACE. Regarding hypercholesterolemia, this 339 
conventional risk factor is likely to be confounded by indications for statin treatment. Indeed, 340 
in the ADAPT-DES registry(16) hyperlipidemia was protective against mortality with a 341 
HR=0.60 (0.41–0.86) and was not prognostic of MACE in post-ACS patients with optimal 342 
medical therapy(40). In addition, hypercholesterolemia was not homogeneously defined 343 
across the studies in the present meta-analysis and other markers, such as plasma LDL-344 
cholesterol levels, were not widely available.  345 
When PR was evaluated using 5 µM ADP, its interaction with the level of cardiovascular risk 346 
for the prediction of MACE was of a similar magnitude, although non-significant. These 347 
findings may reflect the lower number of patients available in studies using 5 µM ADP, and a 348 
Page 14 of 127Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
corresponding loss of power. Moreover, it was previously shown that ADP-induced platelet 349 
aggregation in citrated plasma was dependent on the artifactual generation of TxA2 that was 350 
modulated by aspirin, at least at lower ADP concentrations(41). This may be associated with 351 
an additional background noise in which the interaction between the identified risk factors 352 
and PR to predict MACE is blurred, as seen with the lowest 5 µM ADP concentrations and 353 
partially also with the intermediate 10 µM ADP concentrations. Only four of the studies 354 
analysed used 10 µM ADP, and two of these had a follow-up limited to 30 days; with only 355 
124 MACEs during follow-up, this accounts for a limitation in power to reliably study 356 
interactions. Overall, the concentration of ADP used is of limited significance since the 357 
influence of risk factors appears in all three ADP concentration groups (table 3 and figure 2). 358 
Which laboratory assay and which platelet agonist concentration are best suited for the 359 
clinical evaluation of platelet function is the matter of some debate. ADP-induced LTA is 360 
highly reproducible within a given laboratory, but its lack of standardization across studies 361 
may have slightly weakened the positiv  findings or lower the level of significance for the 362 
interactions found in the present meta-analysis. Of note, the present meta-analysis does not 363 
aim to promote the use of LTA to tailor antiplatelet therapy but it rather relied on a historical 364 
gold standard in platelet function testing to evidence an interaction with patients’ 365 
characteristics that should be considered for a tailored approach.  The point-of care 366 
VerifyNow P2Y12 assay, used in several intervention trials, correlates well with ADP-induced 367 
LTA(42, 43) and we speculate that the main findings of the present meta-analysis would 368 
have been similar, had PR been evaluated using the VerifyNow P2Y12 assay.  369 
 Several intervention trials have compared conventional clopidogrel treatment to an 370 
antiplatelet strategy tailored according to PR. Early, small randomized trials(11, 12) that 371 
utilized vasodilator-stimulated phosphoprotein phosphorylation level measurement to indicate 372 
P2Y12 receptor reactivity, showed a protective effect for repeat 600 mg clopidogrel loading 373 
doses in ACS patients prior to PCI. However, recent larger trials utilizing the VerifyNow P2Y12 374 
assay were negative. Indeed, the GRAVITAS(13) and ARCTIC(14) studies failed to show the 375 
benefit of a PR-tailored antiplatelet strategy after PCI. Various limitations of these trials were 376 
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addressed in a recent consensus publication(22). The event rate of the GRAVITAS study 377 
was low compared to the one used for power calculation, and the antiplatelet effect of the 378 
high-dose regimen may have been suboptimal as it reduced the prevalence of high PR by 379 
only 22%. Similarly, the ARTIC study population was also at a low absolute risk of 380 
subsequent cardiovascular events because the prevalence of ACS patients was low, and the 381 
composite endpoint also included other events that may not be related to platelet function. 382 
The interaction of PR and the number of risk factors, as identified in the present meta-383 
analysis, substantiates the hypothesis that the risk associated with high PR was not clinically 384 
relevant in low-risk patients, and that any measure aiming to lower PR is unlikely to lead to a 385 
beneficial reduction of MACE for these low-risk patients. Based on these observations we 386 
speculate that higher risk patients are more likely to benefit from a therapy tailored to their 387 
initial PR. This may explain why early interventions designed to efficiently blunt high PR in 388 
ACS patients with multiple conventional risk factors translated into a reduction of MACE(11, 389 
12, 22).  390 
In the current new antiplatelet era, prasugrel and ticagrelor have a major part to play in the 391 
management of ACS, leaving clopidogrel as an alternative for patients with high bleeding risk. 392 
However, a recent cost-effectiveness analysis for six European perspectives showed that the 393 
universal use of newer P2Y12 inhibitors for ACS patients is probably not as cost-effective as 394 
strategies based on PR(44). It should also be kept in mind that ticagrelor and prasugrel 395 
increase the risk of bleeding and that a therapeutic medium-PR window is associated with 396 
optimal net clinical benefit(22). The net benefits of newer P2Y12 inhibitors could also probably 397 
be improved not only by testing for PR, but also by incorporating patient risk levels in the 398 
decision-making process. Although ongoing trials on tailored P2Y12 strategies, including 399 
TROPICAL-ACS (ClinicalTrials.gov identifier: NCT01959451)  and ANTARCTIC(45) partly 400 
include this concept of risk levels, further efforts in this direction are needed.  401 
This meta-analysis has several strengths, such as the good overall quality of the studies 402 
included, as assessed using a quality tool specifically adapted to prognostic studies. The 403 
availability of individual patient data allowed a reliable evaluation of the risk associated with 404 
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PR and of the interaction with vascular risk factors. Readily available risk factors relevant to a 405 
secondary prevention population were thus identified. The consistency of results across the 406 
different ADP concentrations used in the different studies to assess PR, as well as the 407 
sensitivity analyses, indicated that the results were robust.  408 
Despite the advantages related to the availability of individual patient data, this meta-analysis 409 
also had some limitations, including a low proportion of women (25%). This did not allow a 410 
stratification of the analyses by gender, as is usually the case in risk assessment tools such 411 
the European SCORE or the Framingham risk score. Indeed, in these latter scores gender is 412 
not considered as one of traditional risk factors, but is rather presented in separate charts for 413 
women and men. There were incomplete data on concomitant medications or other relevant 414 
risk factors such as the left ventricular ejection fraction, cholesterol levels or renal 415 
insufficiency. Finally, information on bleeding was limited to five studies and a low number of 416 
events, thus precluding a reliable analysis of bleeding events and their relation to PR.      417 
In conclusion, high PR in patients on clopidogrel is associated with an increased risk of 418 
MACE in patients with vascular risk factors, but not in low-risk patients. These findings 419 
suggest that trials on tailored PR treatment strategies should be primarily stratified on the 420 
individual vascular risk factors in order to assess a truly personalized approach.  421 
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Table 1. Main characteristics of published studies  631 
 632 
Study 
Years of 
publication 
Patients 
(n) 
Age 
(y) 
Male 
(%) 
Diabetics 
(%) 
Smokers 
(%) 
Hyper-
tension 
(%) 
Hypercholes-
terolemia 
(%) 
ACS at 
inclusion 
(%) 
PCI  
(%) 
GpIIb/IIIa 
inhibitor 
(%) 
Follow-up  
(months)* 
ADP 
(µM) 
Campo et al.(27) 2006 70 64±13 69 19 37 63 34 100 100 100 10 (15) 5, 20 
Hochholzer et al.(28) 2006 765 66±9 78 24 11 82 92 0 100 0 12 (12) 5, 20 
Angiolillo et al.(29) 2007 173 67±9 65 100 13 65 68 0 0 0 24 (36) 20 
Cuisset et al.(30) 2007 190 65±12 76 33 48 58 53 87.4 100 14.7 1 (1) 10, 20 
Geisler et al.(31) 2008 1,092 67±11 74 33 39 80 59 51.7 100 7.7 1 (1) 20 
Gurbel et al.(32) 2008 297 65±12 65 41 55 74 82 0 100 42 24 (24) 5, 20 
Cuisset et al.(33) 2009 598 65±12 78 35 39 56 55 100 100 9.9 1 (1) 10 
Yong et al.(34) 2009 248 63±12 71 22 27 53 52 100 55 39.7 6 (21) 5, 10, 20 
Breet et al.(35) 2010 1,069 64±11 75 81 11 77 80 0 100 7.0 12 (12) 5, 20 
Marcucci et al.(36) 2010 1,108 69±10 75 24 23 66 55 100 100 26.0 12 (12) 10 
Beigel et al.(37) 2011 174 59±12 83 27 41 51 45 100 100 - 6 (6) 5 
Aradi et al.(38) 2012 160 62±9 63 38 36 84 50 0 100 0 12 (12) 5 
Reny et al.(8) 2012 534 62±12 82 21 20 56 63 0 0 0 32 (50) 5, 20 
Age, mean ± standard deviation; CAD, coronary artery disease; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; ADP, 633 
adenosine diphospate concentration used for the evaluation of platelet reactivity  634 
* Median (maximum) 635 
  636 
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Table 2: Multivariate analysis to assess the associations between the risk factors and the composite outcome of MACE. This analysis was 637 
conducted on the patients of the 13 studies of the meta-analysis (n=6,256 after exclusion of missing data). MACE were observed in 412 patients. 638 
Hazard ratios (HR) greater than one show an increased risk of MACE in patients having the corresponding risk factor.   639 
Factors collected in studies Adjusted HR [95% CI] p Level of risk of MACE * HR [95% CI] p 
Current smoking status 0.92 [0.71;1.18] 0.50 Low risk (n=579) 1 
 Age (> 75) 1.56 [1.25;1.95] <0.0001 Intermediate risk (n=2444) 1.61 [1.05;2.45] 0.03 
Diabetes 1.58 [1.27;1.96] <0.0001  High risk (n=3435) 2.58 [1.69;3.94] <0.0001 
Hypercholesterolemia 0.86 [0.69;1.06] 0.15 
   Hypertension 1.23 [0.98;1.54] 0.07 
   ACS at inclusion 2.00 [1.27;3.16] 0.003 
   Gender (Male) 1.11 [0.89;1.40] 0.35     
*: a surrogate for the level of risk was defined as the number of risk factors (among age, diabetes, hypertension, and ACS at inclusion): low risk for 640 
no risk factor, intermediate risk for one risk factor and high risk for two or more risk factors). 641 
 642 
  643 
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Table 3: Associations between the ADP induced-aggregation categories and the composite outcome of MACE with adjustment on the factors 644 
collected in the studies of the meta-analysis (factors shown in Table 2). 645 
ADP 20 µM ADP 10 µM ADP 5 µM 
N N N 
Studies 9 
 
4 
 
8 
 
Events 287 
 
124 
 
229 
 
Patients (after exclusion of missing data) 4,140 
 
2,077 
 
3,160 
 
 
HR [95% CI] p HR [95% CI] p HR [95% CI] p 
ADP induced-aggregation categories 
 
0.0003** 
 
0.03** 
 
0.02** 
Lower category * 1 
 
1 
 
1 
 
 Intermediate category * 1.85 [1.26;2.73] 0.002 1.31 [0.79;2.17] 0.30 1.79 [1.02;3.14] 0.04 
 Higher category * 2.91 [1.78;4.74] <0.0001 2.61 [1.64;4.16] <0.0001 2.79 [1.50;5.22] 0.001 
HR, Hazard Ratio; CI, Confidence Interval 646 
* Categories for ADP 20 and 10 µM are 0%-40%, 41%-60%, 61%-100%, and for ADP 5 µM are 0%-30%, 31%-50%, 51%-100% 647 
**: global p-values for testing the hypothesis that both HRs (intermediate- and higher-ADP induced-aggregation category) equal 1 648 
 649 
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Table 4: Reclassification of the 6-month risk of MACE when the individual risk was predicted from platelet reactivity measured by 20µM ADP in 650 
addition to risk factors. The predicted risk was stratified in three levels (low: ≤3%, intermediate: >3% and ≤5%, high: >5%) in agreement with the 6-651 
month risk observed in patients with none, one and two or more risk factors (2.3%, 4.1% and 6.2% respectively). Patients were stratified according 652 
to their number of risk factors and to the level of the predicted risk. The numbers of patients and, in brackets, the corresponding observed 6-month 653 
risk of MACE in each stratum. 654 
  
Risk predicted by the combination of risk factors and platelet reactivity measured by 
20µM ADP  
Risk predicted by the number of risk 
factors only Low risk (≤3%)  
Intermediate risk (>3% 
and ≤5%)   
High risk 
(>5%)  Total 
Low risk  - no risk factor 524 * (2.4% **) 26 * 0 * 550 * (2.3% **) 
Intermediate risk - one risk factor 625 * (2.1% **) 576 * (3.7% **) 
622 * 
(6.3% **) 1823 * (4.1% **) 
High risk - two or more risk factors 102 * (0.0% **) 462 * (3.0% **) 
1256 * 
(7.6% **) 1820 * (6.2% **) 
Total 1251 * (2.1% **) 1064 * (3.4% **) 
1878 * 
(7.1% **) 4193 * (4.7% **) 
 *: number of patients  655 
**: observed 6-month risk of MACE  656 
 657 
  658 
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Figure 1: Flow chart of the meta-analysis 659 
 660 
661 
9 duplicate data
29 excluded studies (non-prospective, no 
clinical endpoint, no ADP aggregation, non 
english)
7 excluded studies (5 not responding to 
requests, 2 refusals; not providing data for a 
total of 557 patients). 
1,995 identified references
58 full-text  articles 
assessed for eligibility 
13  included studies 
totaling 6,478 patients
1,937 excluded references (duplicates between 
databases, animal, no clinical endpoint, non-
prospective, no ADP aggregation)
20 qualifying studies
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Figure 2: Kaplan-Meier survival curve for the occurrence of MACE  662 
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Figure 3: Association between platelet reactivity and the occurrence of MACE according to 665 
the level of risk. Low-risk patients have none of the risk factors (among age > 75 years, acute 666 
coronary syndrome at inclusion, diabetes, and hypertension), intermediate-risk patients have 667 
one risk factor and high-risk patients have two or more risk factors. PR was assessed with 20 668 
µM ADP LTA. 669 
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Figure 4: 6-month risk of MACE according to platelet reactivity in the different risk groups. The dashed line represents the overall risk, ignoring 
platelet reactivity and the black line shows the risk according to the platelet reactivity assessed with 20 µM ADP LTA, in patients with no risk 
factors (A), one risk factor (B) and two or more risk factors (C).  
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Abstract  49 
Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) 50 
and the risk of major adverse cardiovascular events (MACE). However, large intervention 51 
trials on PR-tailored treatments have been neutral. The role and usefulness of PR with 52 
regard to levels of cardiovascular risk are unclear. We undertook a systematic review and 53 
meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes 54 
(ACS), ischemic strokes, and vascular deaths) in relation to PR and its interaction with 55 
cardiovascular risk levels. PR was determined using ADP-induced light transmission 56 
aggregometry with a primary concentration of 20µM ADP.Thirteen prospective studies 57 
totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5%) during a 58 
median follow-up of 12 months. The strength of the association between the risk of MACE 59 
and PR increased significantly (p=0.04) with the number of risk factors present (age>75 60 
years, ACS at inclusion, diabetes, and hypertension). No association was detected in 61 
patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was 62 
associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk 63 
factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-64 
PR: HR=3.7, p=0.0003). PR allowed the reclassification of 44% of the total population to a 65 
different risk level for the outcome of MACE, mostly in intermediate or high risk patients. 66 
 In conclusion, the magnitude of the association between PR and MACE risk is strongly 67 
dependent on the level of cardiovascular risk faced by patients on clopidogrel. 68 
 69 
Keywords: clopidogrel, drug response, platelets, cardiovascular diseases, ischemic events. 70 
 71 
  72 
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Introduction 73 
Atherosclerotic diseases account for more than 40% of deaths in Western countries, and 74 
antiplatelet therapy is a major preventive strategy in this setting(1). Clopidogrel, a P2Y12 75 
receptor blocker, inhibits the activation of platelets by adenosine diphosphate (ADP), and is 76 
widely prescribed for secondary prevention in patients with atherosclerotic diseases. When 77 
combined with aspirin, clopidogrel is particularly effective in patients with acute coronary 78 
syndromes (ACS)(2), and has proved superior to aspirin alone in several other large 79 
randomised controlled trials. The pharmacodynamic response to clopidogrel shows a wide 80 
inter-individual variability(3, 4). Numerous cohort studies, often performed on patients with 81 
acute coronary syndrome (ACS) and/or undergoing percutaneous coronary interventions 82 
(PCI), have shown an association between high on-treatment platelet reactivity (PR) and the 83 
risk of recurrent major adverse cardiovascular events (MACE)(5-7). However, recent studies 84 
in cohorts of stable cardiovascular outpatients(8, 9) or in medically managed ACS 85 
patients(10) failed to confirm these results. Several randomized trials aimed at reducing the 86 
recurrence of ischemic events have compared standard clopidogrel treatment to a P2Y12-87 
inhibitor strategy tailored according to the presence of high PR. Although initial small trials 88 
were promising(11, 12) more recent larger trials showed no benefit from adjusting clopidogrel 89 
doses or switching to prasugrel based on PR testing in low-risk coronary patients undergoing 90 
PCI(13, 14). These contrasting results, both from observational studies and randomized 91 
intervention trials, may be explained by different patient characteristics including the level of 92 
risk, but to date few data substantiate these hypotheses. We previously showed, in a study-93 
level meta-analysis, that the risk of recurrent MACE associated with high PR was greater in 94 
studies using GpIIb/IIIa inhibitors (a marker of high-risk patients) than in studies which did 95 
not(7). Another meta-regression from a study-level meta-analysis of randomized trials 96 
suggested that the higher the incidence of coronary stent thrombosis in a given study, the 97 
larger the net clinical benefit from a PR-tailored strategy(15). Finally, the ADAPT-DES 98 
registry of patients undergoing PCI showed that high PR was predictive of stent thrombosis 99 
mostly in ACS patients, but there was no interaction reported between PR and the presence 100 
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of an ACS at inclusion(16). This information suggests the hypothesis that high PR might be 101 
more relevant in high-risk populations, but convincing data at the individual level are lacking. 102 
To date, the only meta-analysis on individual patient data performed on 6 studies totaling 103 
3,059 patients assessed with the VerifyNow P2Y12 assay did not explore this hypothesis(17). 104 
Similarly, one of the largest and more recent meta-analysis on 8 studies and 4817 patients 105 
did not explore this interaction due to the lack of individual data(18). To further investigate 106 
this interaction on a larger population we performed a collaborative meta-analysis of 107 
individual patient data and focused on the interaction between relevant vascular risk factors 108 
and PR, assessed with ADP induced light transmission aggregometry (LTA), in order to 109 
better define the risk of MACE.  ADP-induced LTA is the assay upon which all P2Y12 receptor 110 
inhibitors have been developed, thus supporting its use in the present meta-analysis. In 111 
addition, among several available assays to evaluate PR, LTA is the historical gold standard 112 
with which most platelet function assays were compared.   113 
  114 
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Methods 115 
Data sources 116 
Literature review, confined to articles in English(19), was based on electronic databases 117 
(Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials) and 118 
abstracts from major international meetings held from 2010–2013 (ISTH, AHA, ACC, ESC). 119 
A free-text search was conducted using an ‘ADP’ and ‘aggregation’ and ‘clopidogrel’ key-120 
word combination. Articles were selected on the basis of abstracts, before examination of the 121 
full text. Reference lists of selected articles were also hand-searched to identify additional 122 
relevant reports. Reviewers (JLR and PF) were not blinded to the journal, authors or 123 
institutions in the publications as this has been shown to be unnecessary(20). The electronic 124 
database search was last updated on 31 July, 2013. The objective of this individual patients’ 125 
data meta-analysis was described in a project that was part of French ministry of health’s 126 
initiative to encourage meta-analyses (PHRC 15-07 to JL Reny “Etudes prospectives sur la 127 
réponse biologique au clopidogrel et évènements ischémiques chez les patients 128 
athérothrombotiques : Métaanalyse sur données individuelles et résumées” http://www.plan-129 
alzheimer.gouv.fr/IMG/pdf/Liste_des_dossiers_retenus_-_2_mai_2008.pdf ). Protocol in 130 
French available upon request.    131 
 132 
Study selection 133 
Selected studies met the following criteria: (a) patients were treated with clopidogrel and had 134 
symptomatic atherothrombosis (clinical signs related to vascular atherothrombotic lesions); 135 
(b) pharmacodynamic response to clopidogrel was evaluated using the maximal aggregation 136 
value from LTA on platelet-rich plasma with 20, 10, or 5 µM ADP as an agonist; (c) LTA was 137 
performed remote from platelet function interfering drugs such as GpIIb/IIIa inhibitors; (d) 138 
patients were prospectively monitored for MACE for at least 30 days, defined using at least 139 
one of the following items: acute coronary syndrome (unstable angina, myocardial infarction 140 
with/without ST segment elevation), ischemic stroke (acute neurological deficit due to a 141 
cerebral infarction), and vascular death; (e) studies involved either a prospective cohort or a 142 
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randomised therapeutic trial, but one in which treatment was allocated independently of the 143 
response to clopidogrel. When studies were suspected of including the same patients, the 144 
authors were asked to provide data from the largest possible number of independent patients.  145 
 146 
Data extraction 147 
The corresponding authors or principal investigators of eligible studies were contacted and 148 
asked to participate in the CLOpidogrel and Vascular ISchemic events – Individual Patient 149 
Data (CLOVIS-IPD) meta-analysis group. Investigators provided individual data on: the 150 
qualifying cardiovascular condition and clinical setting at inclusion (ACS or stable disease); 151 
MACE and date of occurrence during follow-up; platelet reactivity (PR) with ADP 20, 10, 152 
and/or 5 µM and its timing relative to loading dose of clopidogrel; age, gender, height, and 153 
weight; current smoking status, diabetes, hypercholesterolemia, and hypertension; left 154 
ventricular ejection fraction; platelet count; PCI; use of GpIIb/IIIa inhibitors and timing; 155 
concomitant medications; and bleeding events and timing during follow-up. Data were 156 
checked for completeness and consistency with published reports. Any discrepancies were 157 
resolved with the corresponding authors. After format harmonization, data were compiled for 158 
statistical analysis. All studies were approved by their respective institutional review boards.  159 
 160 
Quality assessment of studies  161 
A new quality assessment tool for prognostic studies called PROBAST (see 162 
Acknowledgements) was used to estimate risks of bias and concerns about applicability. As 163 
PROBAST is not customized for meta-analyses of individual patient data, items were 164 
adapted accordingly. Based on the present study’s list of relevant criteria, risks of bias, and 165 
concerns about applicability are rated as low, unclear, or high. Supplemental Figure 1 shows 166 
the list of criteria. 167 
 168 
Primary outcomes and measures 169 
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The primary clinical outcome was the occurrence of MACE, as defined above (see Study 170 
selection (d)). The primary biological outcome was maximal aggregation with 20 µM ADP, as 171 
it is a better concentration for analyzing the effects of clopidogrel than lower ones. PR was 172 
categorized in three strata. The higher cut-offs were selected on the basis of previously 173 
published cut-offs (59% to 64% for 20 µM ADP, and 43% to 46% for 5 µM ADP)(21), and to 174 
keep relatively balanced numbers of patients in each PR categories. Three pre-specified 175 
categories allowed a better description of the dose-dependent effects of PR on the risk of 176 
MACE compared to the usual dichotomous high and low PR categorization. Three categories 177 
were also chosen to better parallel the analysis with a therapeutic PR window that has been 178 
associated with optimal net clinical benefit(22).  A surrogate for the level of cardiovascular 179 
risk was defined as the number of factors with homogeneous definitions across studies, and 180 
these were markers of MACE in the meta-analysis. The factors were selected from among 181 
age, diabetes, hypertension, smoking, hypercholesterolemia, and the presence of an ACS at 182 
inclusion (as defined in study selection (d)), and were all provided at the time of inclusion and 183 
PR testing.  184 
 185 
Statistical analysis  186 
MACE-free survival curves were derived from individual patient data using the Kaplan-Meier 187 
estimator; curves were compared using log-rank tests stratified by study. Associations 188 
between conventional risk factors, PR strata, and risk of MACE were analyzed using 189 
multivariate, mixed-effect Cox models. The amount of heterogeneity was assessed by the 190 
size of the random effects (Tau2) which is an estimate of the between study variability(23). 191 
The presence of heterogeneity was tested by comparing models with and without random 192 
effects (likelihood ratio test). The interactions between the level of risk and PR strata were 193 
tested. MACE-free survival according to PR, as a continuous variable, was assessed using 194 
the R package prodlim using the symmetrical nearest neighborhoods method.(24) Sensitivity 195 
analyses were conducted to check the robustness of the findings with respect to: the risks of 196 
bias and concerns about the applicability of studies; the definition of MACE, including target 197 
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vessel revascularization or PCI at inclusion, and; the influence of a given specific study. The 198 
net reclassification index (NRI) for survival data(25) was computed to quantify the 199 
contribution of PR testing for the prediction of the 6-month risk of MACE in patients with 200 
increasing numbers of traditional risk factors. The event and non-event continuous NRIs 201 
were reported. Potential publication bias was checked for. P-values below 0.05 were 202 
considered significant and all tests were two-sided. Published guidelines for meta-analysis of 203 
observational studies in epidemiology (MOOSE) and their reporting(26) were followed. 204 
Details on statistical methods are given in the online data supplement.  205 
 206 
Results 207 
Characteristics of included studies 208 
The Figure 1 flow-chart details how 13 of 20 qualifying studies were included, totaling 6,478 209 
patients(8, 27-38). Table 1 shows their characteristics. Data on body mass index, 210 
concomitant medications, left ventricular ejection fraction, or the occurrence of target and 211 
non-target vessel revascularization during follow-up were only available in some studies. All 212 
studies provided individual data allowing a homogeneous definition of MACE, current 213 
smoking status, ACS, diabetes (fasting plasma glucose ≥ 7.0 mmol/l, 2-h plasma glucose ≥ 214 
11.1 mmol/l after 75g oral glucose load or background therapy for diabetes), and 215 
hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or 216 
a documented history of hypertension). Hypercholesterolemia was not defined in a 217 
homogeneous fashion across studies and plasma LDL-cholesterol levels were not available 218 
for more than 2,000 patients. Overall, risks of bias and concerns about applicability were low 219 
(online data supplement further details study characteristics, bias, and applicability). 220 
Information on bleeding was limited to five studies, with only 67 major and 20 221 
moderate/minor bleedings.  222 
 223 
MACE and level of risk  224 
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Overall, 421 MACE occurred in 6,478 patients (6.5%), the majority being ACS (n = 383). 225 
There were 83 stent thromboses, including 79 definite or probable and four possible ones, all 226 
included in the composite outcome of MACE.  The MACE-free survival rate across the 227 
different studies at the end of follow-up ranged from 77.4% to 97.3%. In a multivariate 228 
analysis, four factors were found relevant to determining patients’ levels of risk: age greater 229 
than 75 years, diabetes, ACS at inclusion, and hypertension (Table 2). The number of these 230 
factors was used as a surrogate for the individual risk of MACE. Patients with none of these 231 
factors were classified ‘low-risk’, patients with one factor ‘intermediate-risk’, and patients with 232 
two or more factors ‘high-risk’ (global p-value <0.0001 for the trend). 233 
 234 
MACE and PR  235 
Nine studies (n = 4,438 patients) performed LTA using 20 µM ADP, four studies (n = 2,144 236 
patients) used 10 µM ADP, and eight studies (n = 3,317 patients) used 5 µM ADP. Figure 2 237 
shows the MACE-free survival curves by category of ADP concentration. Risk of MACE 238 
increased significantly with PR with 20 µM ADP, 10 µM ADP, and 5 µM ADP.  239 
With adjustment, high PR was still significantly associated with an increased risk of MACE 240 
(Table 3). However, for PR evaluated using 10 µM ADP, risk only increased for the highest 241 
PR category, corresponding to LTA values greater than 60%.  242 
 243 
Interaction between risk level and PR for the outcome of MACE 244 
 245 
Platelet reactivity assessed with 20 µM ADP. Patients with none of the four risk factors 246 
showed no significantly increased risk associated with PR, while for patients with one risk 247 
factor only, the higher strata of PR was associated with an increased risk of MACE. Patients 248 
with two or more risk factors showed an increased risk of MACE for both the medium and 249 
higher strata of PR. (Figure 3). In a Cox model, the interaction between PR strata and the 250 
risk level was statistically significant (p=0.04). The corresponding hazard ratios (HRs) are 251 
shown in Figure 3. Heterogeneity was not detected for the overall interaction (p=0.81), as 252 
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10 
well as when it was restricted to each risk level category (intermediate versus low risk level, 253 
p=0.45, and high versus low risk level, p=0.90). Additional results on heterogeneity are 254 
provided in the supplemental material. Figure 4A shows that PR, when analyzed in a 255 
continuous fashion, barely affects the risk of MACE at 6 months in patients with no risk 256 
factors:  the risk is close to 2% at six months, irrespective of the level of platelet reactivity. 257 
Conversely, patients with one risk factor and an overall 4.1% risk of MACE at six months 258 
have in fact a 2% risk of MACE when they have a low PR, or a 6% risk of MACE when they 259 
have a high PR (Figure 4B). Similarly, patients with two or more risk factors and an overall 260 
6% risk of MACE at six months can indeed have a 2% risk of MACE when they have a low 261 
PR (Figure 4C). The reclassification of the 6-month risk of MACE, according to the three 262 
categories of platelet reactivity, in patients with no, one and two or more risk factors, is 263 
shown in Table 4. Overall, PR allowed the reclassification of 44% of the total population 264 
(1837/4193 patients) included in a 6-month follow-up to a different level, mostly in patients 265 
originally identified as intermediate or high risk on the basis of the number of risk factors only. 266 
In patients experiencing MACE in the first 6 months of follow-up, the risk predicted by the 267 
combination of PR and risk factors was on average increased compared with the risk 268 
predicted from risk factors only: the continuous event net reclassification index (NRI) was 269 
0.39 (95%CI 0.23 to 0.62). Conversely, in patients free of MACE at 6 months, the measure of 270 
PR did not modify the predicted risk: the continuous non-event NRI was 0.01 (95%CI -0.16 to 271 
0.09). The overall NRI was 0.39 (95%CI 0.22 to 0.57). 272 
 273 
Platelet reactivity assessed with 10 µM ADP. A total of only five low-risk patients in four 274 
studies performing 10 µM ADP LTA to assess PR precluded an analysis of this low-risk 275 
group. Furthermore, the surrogate for risk level failed to demonstrate an association with the 276 
observed risk of MACE in these studies. Figure 4B shows that the risk of MACE increased in 277 
both intermediate- and high-risk patients for PR values above 40%, without any obvious 278 
relation with the level of risk.  279 
 280 
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Platelet reactivity assessed with 5 µM ADP. The direction of interaction between PR using 5 281 
µM ADP and the risk level was similar to that observed for PR using 20 µM ADP, even 282 
though overall interaction did not reach the significance level (p=0.17). Of note there were 283 
980 fewer patients in the studies performing 5 µM ADP than in those using 20 µM ADP. The 284 
increased risk of MACE as PR increases is indeed similar for intermediate- and high-risk 285 
patients; for low-risk patients PR is not associated with a MACE outcome (online data 286 
supplement). Heterogeneity was not detected for the overall interaction (p=0.19). Figure 4C 287 
shows that the risk of MACE was unaffected by PR in low-risk patients while it increased for 288 
PR values above 30% in intermediate-risk patients and for PR values above 10%–20% in 289 
high-risk patients. 290 
 291 
Sensitivity analyses 292 
Sensitivity analyses were performed for PR using 20 µM ADP to assess: the robustness of 293 
the association between PR and risk of MACE and its interaction with the level of 294 
cardiovascular risk; the robustness of the results in the population of PCI patients and when 295 
target vessel revascularization is added to the composite outcome. All analyses showed that 296 
the sizes of the effects remained similar, and whilst in some instances the statistical 297 
significance of the interactions could be lost, there was no impact on their magnitudes 298 
(supplemental Tables 1 and 2). Notably, when PR was categorized in quartiles (20 µM ADP 299 
maximal aggregation quartiles = 0%–38.1%, 38.2%–51.3%. 51.4%–63.0%, 63.1%–100%) 300 
the interaction between PR and the number of risk factors remained significant (p=0.01). 301 
When restricted to the population of 3,564 patients treated with PCI and tested using 20 µM 302 
ADP the interaction was of similar magnitude but no longer significant (supplemental Table 303 
3). 304 
 305 
Publication and availability biases 306 
A check for potential publication bias was made for PR using 20 µM ADP, on which the main 307 
analyses were performed. A funnel plot was obtained by representing the HR of PR using 20 308 
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µM ADP and the standard error, assessed in each separate study (supplemental Figure 4). 309 
Two studies with a negative association between PR using 20 µM ADP and the risk of MACE 310 
(with small sample sizes) were detected as missing using the ‘trim and fill’ method for making 311 
the funnel plot symmetrical. When these missing studies were added, the pooled HR was not 312 
significantly modified. These findings suggested that the publication bias in our meta-analysis 313 
was minor.  314 
Seven qualifying studies could not provide individual patient data. It is of note that in five of 315 
these, the relation between clopidogrel non-response and ischemic events was not a study 316 
objective (pharmacokinetic-pharmacodynamic studies or randomized trials of different 317 
clopidogrel loading doses). The two remaining studies (n = 101 and 111 patients) were 318 
specifically interested in the prognostic value of PR for MACE.  319 
  320 
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Discussion 321 
In the present meta-analysis of individual patient data conducted in a representative panel of 322 
clopidogrel-treated patients we demonstrated that the association between PR and the risk of 323 
MACE depended strongly on the level of cardiovascular risk. When using 20 µM ADP, the 324 
most commonly used concentration in LTA, the risk of MACE associated with PR increased 325 
with the level of cardiovascular risk. Indeed, PR did not affect the risk of MACE in patients 326 
presenting no risk factors, however it gradually increased the risk of MACE as the number of 327 
cardiovascular risk factors increased, reaching a 3.7 times greater risk in high-risk patients 328 
with a high PR. The measure of PR with 20 µM ADP, in addition to risk factors, modified the 329 
interpretation of the 6-month risk of MACE in 44% of patients, mainly in patients with at least 330 
one risk factor. 331 
Interestingly, smoking and hypercholesterolemia were not associated with the outcome of 332 
MACE and were not included in the analysis of the interaction between PR and risk factors. 333 
In randomized controlled trials, the benefit of clopidogrel in reducing the incidence of MACE 334 
is primarily seen in smokers, with little benefit to non-smokers(39). With regard to the cohort 335 
studies of clopidogrel-treated patients included in this meta-analysis, this differential effect 336 
suggests that the increased risk of MACE related to smoking is offset by the benefit 337 
clopidogrel provides to smokers; it thereby weakens any possible analysis of the interaction 338 
between smoking and PR for outcomes of MACE. Regarding hypercholesterolemia, this 339 
conventional risk factor is likely to be confounded by indications for statin treatment. Indeed, 340 
in the ADAPT-DES registry(16) hyperlipidemia was protective against mortality with a 341 
HR=0.60 (0.41–0.86) and was not prognostic of MACE in post-ACS patients with optimal 342 
medical therapy(40). In addition, hypercholesterolemia was not homogeneously defined 343 
across the studies in the present meta-analysis and other markers, such as plasma LDL-344 
cholesterol levels, were not widely available.  345 
When PR was evaluated using 5 µM ADP, its interaction with the level of cardiovascular risk 346 
for the prediction of MACE was of a similar magnitude, although non-significant. These 347 
findings may reflect the lower number of patients available in studies using 5 µM ADP, and a 348 
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corresponding loss of power. Moreover, it was previously shown that ADP-induced platelet 349 
aggregation in citrated plasma was dependent on the artifactual generation of TxA2 that was 350 
modulated by aspirin, at least at lower ADP concentrations(41). This may be associated with 351 
an additional background noise in which the interaction between the identified risk factors 352 
and PR to predict MACE is blurred, as seen with the lowest 5 µM ADP concentrations and 353 
partially also with the intermediate 10 µM ADP concentrations. Only four of the studies 354 
analysed used 10 µM ADP, and two of these had a follow-up limited to 30 days; with only 355 
124 MACEs during follow-up, this accounts for a limitation in power to reliably study 356 
interactions. Overall, the concentration of ADP used is of limited significance since the 357 
influence of risk factors appears in all three ADP concentration groups (table 3 and figure 2). 358 
Which laboratory assay and which platelet agonist concentration are best suited for the 359 
clinical evaluation of platelet function is the matter of some debate. ADP-induced LTA is 360 
highly reproducible within a given laboratory, but its lack of standardization across studies 361 
may have slightly weakened the positive findings or lower the level of significance for the 362 
interactions found in the present meta-analysis. Of note, the present meta-analysis does not 363 
aim to promote the use of LTA to tailor antiplatelet therapy but it rather relied on a historical 364 
gold standard in platelet function testing to evidence an interaction with patients’ 365 
characteristics that should be considered for a tailored approach.  The point-of care 366 
VerifyNow P2Y12 assay, used in several intervention trials, correlates well with ADP-induced 367 
LTA(42, 43) and we speculate that the main findings of the present meta-analysis would 368 
have been similar, had PR been evaluated using the VerifyNow P2Y12 assay.  369 
 Several intervention trials have compared conventional clopidogrel treatment to an 370 
antiplatelet strategy tailored according to PR. Early, small randomized trials(11, 12) that 371 
utilized vasodilator-stimulated phosphoprotein phosphorylation level measurement to indicate 372 
P2Y12 receptor reactivity, showed a protective effect for repeat 600 mg clopidogrel loading 373 
doses in ACS patients prior to PCI. However, recent larger trials utilizing the VerifyNow P2Y12 374 
assay were negative. Indeed, the GRAVITAS(13) and ARCTIC(14) studies failed to show the 375 
benefit of a PR-tailored antiplatelet strategy after PCI. Various limitations of these trials were 376 
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addressed in a recent consensus publication(22). The event rate of the GRAVITAS study 377 
was low compared to the one used for power calculation, and the antiplatelet effect of the 378 
high-dose regimen may have been suboptimal as it reduced the prevalence of high PR by 379 
only 22%. Similarly, the ARTIC study population was also at a low absolute risk of 380 
subsequent cardiovascular events because the prevalence of ACS patients was low, and the 381 
composite endpoint also included other events that may not be related to platelet function. 382 
The interaction of PR and the number of risk factors, as identified in the present meta-383 
analysis, substantiates the hypothesis that the risk associated with high PR was not clinically 384 
relevant in low-risk patients, and that any measure aiming to lower PR is unlikely to lead to a 385 
beneficial reduction of MACE for these low-risk patients. Based on these observations we 386 
speculate that higher risk patients are more likely to benefit from a therapy tailored to their 387 
initial PR. This may explain why early interventions designed to efficiently blunt high PR in 388 
ACS patients with multiple conventional risk factors translated into a reduction of MACE(11, 389 
12, 22).  390 
In the current new antiplatelet era, prasugrel and ticagrelor have a major part to play in the 391 
management of ACS, leaving clopidogrel as an alternative for patients with high bleeding risk. 392 
However, a recent cost-effectiveness analysis for six European perspectives showed that the 393 
universal use of newer P2Y12 inhibitors for ACS patients is probably not as cost-effective as 394 
strategies based on PR(44). It should also be kept in mind that ticagrelor and prasugrel 395 
increase the risk of bleeding and that a therapeutic medium-PR window is associated with 396 
optimal net clinical benefit(22). The net benefits of newer P2Y12 inhibitors could also probably 397 
be improved not only by testing for PR, but also by incorporating patient risk levels in the 398 
decision-making process. Although ongoing trials on tailored P2Y12 strategies, including 399 
TROPICAL-ACS (ClinicalTrials.gov identifier: NCT01959451)  and ANTARCTIC(45) partly 400 
include this concept of risk levels, further efforts in this direction are needed.  401 
This meta-analysis has several strengths, such as the good overall quality of the studies 402 
included, as assessed using a quality tool specifically adapted to prognostic studies. The 403 
availability of individual patient data allowed a reliable evaluation of the risk associated with 404 
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PR and of the interaction with vascular risk factors. Readily available risk factors relevant to a 405 
secondary prevention population were thus identified. The consistency of results across the 406 
different ADP concentrations used in the different studies to assess PR, as well as the 407 
sensitivity analyses, indicated that the results were robust.  408 
Despite the advantages related to the availability of individual patient data, this meta-analysis 409 
also had some limitations, including a low proportion of women (25%). This did not allow a 410 
stratification of the analyses by gender, as is usually the case in risk assessment tools such 411 
the European SCORE or the Framingham risk score. Indeed, in these latter scores gender is 412 
not considered as one of traditional risk factors, but is rather presented in separate charts for 413 
women and men. There were incomplete data on concomitant medications or other relevant 414 
risk factors such as the left ventricular ejection fraction, cholesterol levels or renal 415 
insufficiency. Finally, information on bleeding was limited to five studies and a low number of 416 
events, thus precluding a reliable analysis of bleeding events and their relation to PR.      417 
In conclusion, high PR in patients on clopidogrel is associated with an increased risk of 418 
MACE in patients with vascular risk factors, but not in low-risk patients. These findings 419 
suggest that trials on tailored PR treatment strategies should be primarily stratified on the 420 
individual vascular risk factors in order to assess a truly personalized approach.  421 
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Table 1. Main characteristics of published studies  631 
 632 
Study 
Years of 
publication 
Patients 
(n) 
Age 
(y) 
Male 
(%) 
Diabetics 
(%) 
Smokers 
(%) 
Hyper-
tension 
(%) 
Hypercholes-
terolemia 
(%) 
ACS at 
inclusion 
(%) 
PCI  
(%) 
GpIIb/IIIa 
inhibitor 
(%) 
Follow-up  
(months)* 
ADP 
(µM) 
Campo et al.(27) 2006 70 64±13 69 19 37 63 34 100 100 100 10 (15) 5, 20 
Hochholzer et al.(28) 2006 765 66±9 78 24 11 82 92 0 100 0 12 (12) 5, 20 
Angiolillo et al.(29) 2007 173 67±9 65 100 13 65 68 0 0 0 24 (36) 20 
Cuisset et al.(30) 2007 190 65±12 76 33 48 58 53 87.4 100 14.7 1 (1) 10, 20 
Geisler et al.(31) 2008 1,092 67±11 74 33 39 80 59 51.7 100 7.7 1 (1) 20 
Gurbel et al.(32) 2008 297 65±12 65 41 55 74 82 0 100 42 24 (24) 5, 20 
Cuisset et al.(33) 2009 598 65±12 78 35 39 56 55 100 100 9.9 1 (1) 10 
Yong et al.(34) 2009 248 63±12 71 22 27 53 52 100 55 39.7 6 (21) 5, 10, 20 
Breet et al.(35) 2010 1,069 64±11 75 81 11 77 80 0 100 7.0 12 (12) 5, 20 
Marcucci et al.(36) 2010 1,108 69±10 75 24 23 66 55 100 100 26.0 12 (12) 10 
Beigel et al.(37) 2011 174 59±12 83 27 41 51 45 100 100 - 6 (6) 5 
Aradi et al.(38) 2012 160 62±9 63 38 36 84 50 0 100 0 12 (12) 5 
Reny et al.(8) 2012 534 62±12 82 21 20 56 63 0 0 0 32 (50) 5, 20 
Age, mean ± standard deviation; CAD, coronary artery disease; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; ADP, 633 
adenosine diphospate concentration used for the evaluation of platelet reactivity  634 
* Median (maximum) 635 
  636 
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Table 2: Multivariate analysis to assess the associations between the risk factors and the composite outcome of MACE. This analysis was 637 
conducted on the patients of the 13 studies of the meta-analysis (n=6,256 after exclusion of missing data). MACE were observed in 412 patients. 638 
Hazard ratios (HR) greater than one show an increased risk of MACE in patients having the corresponding risk factor.   639 
Factors collected in studies Adjusted HR [95% CI] p Level of risk of MACE * HR [95% CI] p 
Current smoking status 0.92 [0.71;1.18] 0.50 Low risk (n=579) 1 
Age (> 75) 1.56 [1.25;1.95] <0.0001 Intermediate risk (n=2444) 1.61 [1.05;2.45] 0.03 
Diabetes 1.58 [1.27;1.96] <0.0001  High risk (n=3435) 2.58 [1.69;3.94] <0.0001 
Hypercholesterolemia 0.86 [0.69;1.06] 0.15 
Hypertension 1.23 [0.98;1.54] 0.07 
ACS at inclusion 2.00 [1.27;3.16] 0.003 
Gender (Male) 1.11 [0.89;1.40] 0.35       
*: a surrogate for the level of risk was defined as the number of risk factors (among age, diabetes, hypertension, and ACS at inclusion): low risk for 640 
no risk factor, intermediate risk for one risk factor and high risk for two or more risk factors). 641 
 642 
  643 
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Table 3: Associations between the ADP induced-aggregation categories and the composite outcome of MACE with adjustment on the factors 644 
collected in the studies of the meta-analysis (factors shown in Table 2). 645 
ADP 20 µM ADP 10 µM ADP 5 µM 
N N N 
Studies 9 
 
4 
 
8 
 
Events 287 
 
124 
 
229 
 
Patients (after exclusion of missing data) 4,140 
 
2,077 
 
3,160 
 
 
HR [95% CI] p HR [95% CI] p HR [95% CI] p 
ADP induced-aggregation categories 
 
0.0003** 
 
0.03** 
 
0.02** 
Lower category * 1 
 
1 
 
1 
 
 Intermediate category * 1.85 [1.26;2.73] 0.002 1.31 [0.79;2.17] 0.30 1.79 [1.02;3.14] 0.04 
 Higher category * 2.91 [1.78;4.74] <0.0001 2.61 [1.64;4.16] <0.0001 2.79 [1.50;5.22] 0.001 
HR, Hazard Ratio; CI, Confidence Interval 646 
* Categories for ADP 20 and 10 µM are 0%-40%, 41%-60%, 61%-100%, and for ADP 5 µM are 0%-30%, 31%-50%, 51%-100% 647 
**: global p-values for testing the hypothesis that both HRs (intermediate- and higher-ADP induced-aggregation category) equal 1 648 
 649 
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Table 4: Reclassification of the 6-month risk of MACE when the individual risk was predicted from platelet reactivity measured by 20µM ADP in 650 
addition to risk factors. The predicted risk was stratified in three levels (low: ≤3%, intermediate: >3% and ≤5%, high: >5%) in agreement with the 6-651 
month risk observed in patients with none, one and two or more risk factors (2.3%, 4.1% and 6.2% respectively). Patients were stratified according 652 
to their number of risk factors and to the level of the predicted risk. The numbers of patients and, in brackets, the corresponding observed 6-month 653 
risk of MACE in each stratum. 654 
  
Risk predicted by the combination of risk factors and platelet reactivity measured by 
20µM ADP  
Risk predicted by the number of risk 
factors only Low risk (≤3%)  
Intermediate risk (>3% 
and ≤5%)   
High risk 
(>5%)  Total 
Low risk  - no risk factor 524 * (2.4% **) 26 * 0 * 550 * (2.3% **) 
Intermediate risk - one risk factor 625 * (2.1% **) 576 * (3.7% **) 
622 * 
(6.3% **) 1823 * (4.1% **) 
High risk - two or more risk factors 102 * (0.0% **) 462 * (3.0% **) 
1256 * 
(7.6% **) 1820 * (6.2% **) 
Total 1251 * (2.1% **) 1064 * (3.4% **) 
1878 * 
(7.1% **) 4193 * (4.7% **) 
 *: number of patients  655 
**: observed 6-month risk of MACE  656 
 657 
  658 
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Figure 1: Flow chart of the meta-analysis 659 
 660 
661 
9 duplicate data
29 excluded studies (non-prospective, no 
clinical endpoint, no ADP aggregation, non 
english)
7 excluded studies (5 not responding to 
requests, 2 refusals; not providing data for a 
total of 557 patients). 
1,995 identified references
58 full-text  articles 
assessed for eligibility 
13  included studies 
totaling 6,478 patients
1,937 excluded references (duplicates between 
databases, animal, no clinical endpoint, non-
prospective, no ADP aggregation)
20 qualifying studies
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Figure 2: Kaplan-Meier survival curve for the occurrence of MACE  662 
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Figure 3: Association between platelet reactivity and the occurrence of MACE according to 665 
the level of risk. Low-risk patients have none of the risk factors (among age > 75 years, acute 666 
coronary syndrome at inclusion, diabetes, and hypertension), intermediate-risk patients have 667 
one risk factor and high-risk patients have two or more risk factors. PR was assessed with 20 668 
µM ADP LTA. 669 
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Figure 4: 6-month risk of MACE according to platelet reactivity in the different risk groups. The dashed line represents the overall risk, ignoring 
platelet reactivity and the black line shows the risk according to the platelet reactivity assessed with 20 µM ADP LTA, in patients with no risk 
factors (A), one risk factor (B) and two or more risk factors (C).  
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Rebuttal to BMJ reviewers’ comments 
 
Reviewer: 1 
 
Comments: 
I think this is a fascinating study performed by experts in the field of platelet function analysis. 
There is a clear demonstration of high residual platelet reactivity in treated patients with 
intermediate and high levels of vascular risk factors and its contribution to further adverse 
events. This paper will help redirect further research in this area and could like to significant 
health benefits at if it can be demonstrated that changes in therapy provide better healthcare. 
 
Response : NA 
 
 
 
Reviewer: 2 
 
Comments: 
In the present paper, the relation between platelet reactivity testing and number of vascular 
risk factors is studied affecting major adverse cardiovascular events. The study may add to 
existing literature as intervention studies so far did show the expected benefit in patients with 
low reactivity. 
 
1. The background of the studies included in this meta analysis should be better clarified: 
The differential between purely observational cohorts versus studies in patients undergoing 
revascularization studies. In patients undergoing revascularization the risk for periprocedural 
adverse outcome is considered  especially high in patients with low reactivity but this category 
is not clearly differentiated from the patients receiving secundairy preventive medical 
treatment only. Please make this more clear to the reader. 
 
Response : we fully agree with this comment and purposely provided the information in table 1 on 
patients with ACS and/or PCI at inclusion (a majority of patients). It was likely that in patients with 
ACS, platelet reactivity would play a more important role but it was, up to now, not clearly established 
with strong data. The fact that ACS is a risk factor showing an interaction with platelet reactivity toward 
the outcome of MACE was identified in the present meta-analysis, within the set of risk factors 
associated with the outcome.  
 
 
2. The endpoints are ACS, ischemic stroke and vascular death. Why not including any 
death  ? 
 
Response : these endpoints are consensual and the widely used so-called MACE or MACCE 
endpoints. While we agree that it is important to monitor « all deaths » when performing a clinical trial, 
it may not be relevant to include non-vascular deaths in a composite outcome when a study is 
interested in platelet reactivity and the risk of recurrent thrombotic events. One can speculate that 
platelet reactivity could play a role in cancer-related deaths thereby having an impact on total deaths 
but we were interested in a potential interaction between platelet reactivity and vascular risk factors. In 
order to avoid any diluting or noise effect due to the inclusion of total deaths we restricted our 
composite outcome to ischemic events only. Finally, as the outcome items were pre-specified and did 
not include non-vascular deaths we did not request individual patient data on this latter item and 
cannot perform this analysis now.  
 
3. Did the authors look at separate outcome parameters within this dataset; especially on 
ACS versus stroke leaving vascular death out of the perspective ? 
 
Response : we did not look at each outcome separately or leaving vascular death aside. As mentioned 
in the results section, > 90% of the events were ACS (383 ACS out of 421 MACE), thereby precluding 
a reliable analysis on separate outcomes. Of note, vascular deaths were adjudicated by an 
independent adjudicating committee in some of the included studies.  
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4. Results page 10 line 47: reporting of stent thrombosis as outcome. This was not 
indicated as outcome parameter or it should be that ALL thrombosis led to ACS ? please 
explain. 
 
Response : the information on stent thrombosis is provided as a descriptive statistics. All stent 
thrombosis indeed led to an ACS as this was mentioned in the manuscript (“There were 83 stent 
thromboses, including 79 definite or probable and four possible ones, all included in the composite 
outcome of MACE”)  
 
5. A serious limitation is the use of LTA for PR only. Especially as the authors state in the 
introduction that verify now was never tested likewise it would have seemed easy to also look 
for outcome of verify Now testing. Please explain. Also, make clear in the conclusion section 
that observed results account for LTA only ! 
 
Response: we acknowledge that the conclusion is  supported by LTA data only and this was indeed 
the design of this IPD meta-analysis. We extensively discussed this in the manuscript. The definition of 
PR is given in the abstract, in the introduction, in the methods, in the results and in the discussion. We 
feel that this is clearly stated throughout the manuscript and that the conclusion should remain 
concise. 
As mentioned in the Discussion section, LTA is considered the gold against which all other point of 
care assays were developed. Finally, a meta-analysis on 3 059 individual patient data using the 
VerifyNow assay has been performed, but its power was lower than the present work and the 
interaction with vascular risk was not investigated (Brar SS, ten Berg J, Marcucci R, Price MJ, 
Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet 
reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis 
of individual participant data. J Am Coll Cardiol. 2011;58:1945-1954) 
 
 
6. In all risk prediction models in patients with cardiovascular patients age shows the 
largets effect. please extend more on the relation ship between age as a single risk factor and 
platelet reactivity. 
 
Response: for reviewing purposes we performed the suggested analysis. The category of platelets 
reactivity (measured with ADP 20 µM LTA) was not associated with age (Kruskal-Wallis test: p=0.44): 
the median (IQR) values were 66.0 years (58.0 to 73.9) in the ADP aggregation category 0-40%, 66.0 
years (57.5 to 73.0) in the 41-60% category and 66.2 years (57.5 to 73.3) in the 41-100% category. 
Distributions of age are shown in the Figure below: 
 
In a univariate Cox regression model with a mixed effect to take the clustering into account, age was 
significantly associated with the risk of MACE (HR=1.67 for patients above 75 years versus patients 
below 75 years old, 95%CI 1.35 to 2.07, p<0.0001). 
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In a univariate Cox regression model with a mixed effect to take the clustering into account, the 
category of platelet reactivity was significantly associated with the risk of MACE. The hazard ratios 
compared with the reference 0-40% category were: 
- HR=1.90 (95%CI 1.29 to 2.80, p=0.001) for the 41-60% category 
- HR=3.11 (95%CI 2.12 to 4.57, p<0.0001) for the 61-100% category 
When the association between MACE and platelet reactivity measured by 20 µM ADP aggregation 
was adjusted for age, the hazards ratios for platelet reactivity categories and age of patients were 
similar: 
- HR=1.88 (95%CI 1.28 to 2.77, p=0.001) for the 41-60% category 
- HR=3.01 (95%CI 2.05 to 4.43, p<0.0001) for the 61-100% category 
- HR=1.56 (95%CI 1.20 to 2.02, p=0.001) for age (patients older than 75 years versus patients 
less than 75 years old) 
 
 
In patients younger than 75 years, platelet reactivity was significantly associated with the risk of MACE 
(p<0.0001) and the hazard ratios were: 
- HR=1.55 (95%CI 1.01 to 2.40), p=0.046) for the category 41-60% 
- HR=2.76 (95%CI 1.80 to 4.23), p<0.0001) for the category 61-100% 
In patients older than 75 years old, platelet reactivity was also associated with risk of MACE 
(p=0.0004) and the hazard ratios were greater than for patients younger than 75 years old: 
- HR=3.56 (95%CI 1.48 to 8.56), p=0.005) for the category 41-60% 
- HR=4.15 (95%CI 1.71 to 10.08), p=0.002) for the category 61-100% 
However, the interaction between platelet reactivity and age for prediction of MACE was not 
statistically significant (p=0.12). 
 
These results confirm the overall robustness of the main interaction finding but we believe that this 
type of sub-analysis should not be provided as it complicates the message and is not statistically 
significant.  
 
 
 
7. Conclusion; “suggesting that PR tailored strategies may be most effective in higher 
risk patients” is not warranted based on the data presented in this study. Therefore this 
statement does not belong to the conclusion. 
 
Response: We agree that this may sound too speculative and this was stated only as a suggestion. In 
order to remain conservative and avoid any overstatement we deleted this part of the conclusion 
 
 
Reviewer: 3 
 
Comments: 
This manuscript reports the results of a meta-analysis of individual patient data on the 
relationship of the risk of major adverse cardiovascular events (MACE) to platelet reactivity 
and clinical risk factors in patients treated with clopidogrel prior to percutaneous coronary 
interventions.The study was performed by a team of multinational European investigators with 
experience in epidemiology and clinical cardiology.  The data base analyzed was large (13 
studies including 6478 patients), and the methods used were appropriate.  The paper is well 
organized and clearly written.  The conclusions are supported by the data. 
The results of the study are important.  They make a major contribution to a field of 
investigation that has high clinical relevance, but one that is burdened by methological 
disputes and conflicting outcomes.  The results described provide new understanding of how 
platelet function data might be more usefully interpreted.  A strong virtue of the study is that 
the results are consistent with clinical data.  The paper will be of significant interest to 
clinicians. 
 
Critique: 
1)The number of authors is excessive.  Major contributors should be selected or the work 
presented on behalf of a coalition consistent with BMJ editorial policy. 
 
Response : we very respectfully disagree as all authors had an active participation in the management 
of their own studies, provided their own individual patient data and actively participated to this meta-
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analysis and this manuscript. We kindly ask the editors to allow the inclusion of 20 authors, all 
complying with authorship rules, for this manuscript  
 
2)Page 8, paragrapgh 3:  the statement that 20 micromolar ADP is better requires some 
qualification and references.  It is reasonable to think that a maximal agonist stimulus would be 
the most useful, but it is apparent from the data presented that there is no standard that has 
been uniformly applied. 
 
Response : We fully agree with this comment.  Indeed, it was previously shown that ADP-induced 
platelet aggregation at low concentration (up to 10 microM) in citrated plasma was dependant of the 
artefactual generation of TxA2 that is sensitive to aspirin (Cattaneo M. Aspirin and clopidogrel: 
Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987). 
This may be associated with an additional background noise in which the interaction between the 
identified risk factors and PR to predict MACE is blurred, as seen with the lowest concentrations of 
ADP This was stated in the discussion and the above reference was cited. We have now added a 
clear mention of the “lowest concentration” as 5 micromolar and the intermediate 10 micromolar.  
 
3)Data presented in Table 3 and in Figure 2 could be interpreted to indicate that the 
concentration of ADP used is of limited significance since the influence of risk factors appears 
in all three ADP concentration groups.  this should be discussed by the authors  
  
Response : we fully agree and we have added a sentence with this interpretation. The consistency of 
the interaction independently of ADP concentration further support the main findings of this meta-
analysis. 
 
4)Since the bulk of the work is statistical , the paper should receive careful statistical review. 
 
Response : this was done within the BMJ editorial committee including a statistician, Rafael Perera, 
who did not have any methodological or statistical issues related to this meta-analysis. In addition we 
provide a detailed description of the methods used and several sensitivity analyses that support the 
robustness of the findings (supplemental online material). Finely, we included a quality assessment 
tool, PROBAST, that was recently and specifically designed for meta-analysis or prognostic studies. 
The PROBAST tool was kindly made available to us by Dr Penny Whitting as acknowledged in the 
manuscript.  
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MOOSE checklist designed for meta-analyses of observational studies (1) in lieu of the PRISMA 
checklist(2) focused on meta-analyses of randomized and intervention trials.  
 
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of major adverse 
cardiovascular events in patients on clopidogrel: Systematic review and collaborative meta-analysis of 
individual patient data. Reny JL et al.  
 
Reporting of background should include 
Problem definition: lines 127-128 (Introduction) 
 
Hypothesis statement: lines 132-136 (Introduction)  
 
Description of study outcome(s): line 136 (Introduction), lines 192-207 (Methods) 
 
Type of exposure or intervention used: lines 136-137 (Introduction), lines 192-207 (Methods) 
 
Type of study designs used: line 137 (meta-analysis design, Introduction), lines 162-164 
(designs od studies included in the meta-analysis, Methods) 
 
Study population: lines 154-155 (Methods) 
 
Reporting of search strategy should include: 
Qualifications of searchers (eg, librarians and investigators): investigators, methods p 6 line 
149 
 
Search strategy, including time period included in the synthesis and keywords: lines 143-
151 (Methods) 
 
Effort to include all available studies, including contact with authors: lines 171-173 
 
Databases and registries searched: lines 143-151 (Methods) 
 
Search software used, name and version, including special features used (eg, explosion): 
databases cited in the section ”Methods” only lines 143-145 
 
Use of hand searching (eg, reference lists of obtained articles): lines 148-149 (Methods) 
 
List of citations located and those excluded, including justification: Figure 1 (flow-chart) 
 
Method of addressing articles published in languages other than English: Not applicable.  
 
Method of handling abstracts and unpublished studies: no congress abstract retrieved 
 
Description of any contact with authors: lines 170-181 (Methods) 
 
Reporting of methods should include: 
Description of relevance or appropriateness of studies assembled for assessing the 
hypothesis to be tested: The relevance of studies was guaranteed by the inclusion criteria. Lines 
154-165 
 
Rationale for the selection and coding of data (eg, sound clinical principles or 
convenience): Individual patient’s data. The format of data provided by authors was harmonized 
(standardization of units) – lines 178-181 (Methods) 
 
Documentation of how data were classified and coded (eg, multiple raters, blinding, and 
interrater reliability): Data were not extracted from published papers but provided by authors. The 
list of required variables was provided to authors as well as the definition of the biological and 
clinical outcomes. Data were checked for completeness and consistency with published reports. 
Any discrepancies were resolved with the corresponding authors – lines 178-181 (Methods)   
 
Assessment of confounding (eg, comparability of cases and controls in studies where 
appropriate): the quality of studies, assessed with the PROBAST tool (methods and 
acknowledgements), included the risk of bias related to the outcome measurement, follow-up of 
patients and measure of exposure. Lines 185-189. 
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Assessment of study quality, including blinding of quality assessors; stratification or 
regression on possible predictors of study results: assessment of the quality with the 
PROBAST tool – lines 185-189 (Methods) and supplement Appendix Table 1.  
 
Assessment of heterogeneity: lines 212-215 (Methods) and Supplement Appendix (“Detailed 
statistical analysis”)  
 
Description of statistical methods (eg, complete description of fixed or random effects 
models, justification of whether the chosen models account for predictors of study results, 
dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated : 
lines 209-228 (Methods) and Supplement Appendix ((“Detailed statistical analysis”) 
 
Provision of appropriate tables and graphics: No tables, no graphics in the “Methods” section 
 
Reporting of results should include: 
Graphic summarizing individual study estimates and overall estimate: Individual study 
estimates are not reported because studies were not powered to test the interaction term between 
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Figure 2), lines 459-460 (discussion) 
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Consideration of alternative explanations for observed results: Lines 466-474 
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domain of the literature review) : abstract and discussion lines 383-384, 463-466 
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Abstract  
Objective: Prior studies have shown an association between high on-clopidogrel platelet 
reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large 
intervention trials on PR-tailored treatments have been neutral, possibly owing to the 
inclusion of patients at low cardiovascular risk. The role and usefulness of PR with regard to 
levels of cardiovascular risk are unclear. We assessed the clinical relevance of PR in 
predicting MACE according to patients’ cardiovascular risk levels. 
Design: Systematic review and meta-analysis of individual patient data on MACE outcomes 
(acute coronary syndromes, ischemic strokes, and vascular deaths) in relation to PR and its 
interaction with cardiovascular risk levels. PR was determined using ADP-induced light 
transmission aggregometry (LTA) with a primary concentration of 20µM ADP and defined as 
high (>60% aggregation), medium (41-60%) or low (<41%). A surrogate for the level of 
cardiovascular risk was defined as the number of conventional vascular risk factors with 
homogeneous definitions across studies and identified as predictors of MACE in the meta-
analysis.  Associations between the number of risk factors, PR strata, and risk of MACE were 
analysed using multivariate, mixed-effect Cox models. The net reclassification index (NRI) for 
survival data and the % of patients reclassified to a different risk level were computed to 
quantify the contribution of PR testing for the prediction of the 6-month risk of MACE in 
patients with increasing numbers of traditional risk factors. 
Data sources: Medline, Embase, Web of Science, Cochrane Central Register of Controlled 
Trials) and abstracts from major international meetings held from 2010–2013 (ISTH, AHA, 
ACC, ESC). Free-text search conducted using an ‘ADP’ and ‘aggregation’ and ‘clopidogrel’ 
key-word combination. Inclusion criteria: (a) patients treated with clopidogrel and with 
symptomatic atherothrombosis; (b) response to clopidogrel evaluated using the maximal 
aggregation value from LTA with 20, 10, or 5 µM; (c) LTA performed remote from platelet 
function interfering drugs other than aspirin or clopidogrel; (d) prospective follow-up for 
MACE for at least 30 days; (e) prospective cohort or a randomised therapeutic trial. 
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Corresponding authors of selected studies were contacted to collaborate to the meta-
analysis and to provide their individual patient’s data.  
Results: Thirteen prospective studies totalled 6,478 clopidogrel-treated patients who 
experienced 421 MACE (6.5%) during a median follow-up of 12 months. The risk of MACE 
associated with PR increased differentially according to the number of risk factors present 
(age>75 years, ACS at inclusion, diabetes, and hypertension; interaction p=0.04): no 
association to PR in low-risk patients (no risk factor) (p=0.48); 3.2 (1.6 to 6.5, p=0.001) times 
greater risk of MACE in high PR intermediate-risk patients (one risk factor); 2.9 (1.6 to 5.2, 
p=0.0004) and 3.7 (1.8 to 7, p=0.0003) times greater risk of MACE in medium PR and high 
PR high-risk patients (≥2 risk factors). PR allowed the reclassification of 44% (1837/4193 
patients) of the total population to a different risk level for the outcome of MACE, mostly in 
patients originally identified as intermediate or high risk.  
Conclusion: The magnitude of the association between PR and MACE risk is strongly 
dependant on the level of cardiovascular risk faced by patients on clopidogrel suggesting that 
PR-tailored strategies may be most effective in higher-risk patients. 
 
Keywords: clopidogrel, drug response, platelets, cardiovascular diseases, ischemic events. 
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Atherosclerotic diseases account for more than 40% of deaths in Western countries, and 
antiplatelet therapy is a major preventive strategy in this setting.1 Clopidogrel, a P2Y12 
receptor blocker, inhibits the activation of platelets by adenosine diphosphate (ADP), and is 
widely prescribed for secondary prevention in patients with atherosclerotic diseases. When 
combined with aspirin, clopidogrel is particularly effective in patients with acute coronary 
syndromes (ACS),2 and has proved superior to aspirin alone in several other large 
randomised controlled trials. The pharmacodynamic response to clopidogrel shows a wide 
inter-individual variability.3 4 Numerous cohort studies, often performed on patients with acute 
coronary syndrome (ACS) and/or undergoing percutaneous coronary interventions (PCI), 
have shown an association between high on-treatment platelet reactivity (PR) and the risk of 
recurrent major adverse cardiovascular events (MACE).5-7 However, recent studies in cohorts 
of stable cardiovascular outpatients8 9 or in medically managed ACS patients10 failed to 
confirm these results. Several randomised trials aimed at reducing the recurrence of 
ischemic events have compared standard clopidogrel treatment to a P2Y12-inhibitor strategy 
tailored according to the presence of high PR. Although initial small trials were promising,11 12 
more recent larger trials showed no benefit from adjusting clopidogrel doses or switching to 
prasugrel based on PR testing in low-risk coronary patients undergoing PCI.13 14 These 
contrasting results, both from observational studies and randomised intervention trials, may 
be explained by different patient characteristics including the level of risk, but to date few 
data substantiate these hypotheses. We previously showed, in a study-level meta-analysis, 
that the risk of recurrent MACE associated with high PR was greater in studies using 
GpIIb/IIIa inhibitors (a marker of high-risk patients) than in studies which did not.7 Another 
meta-regression from a study-level meta-analysis of randomised trials suggested that the 
higher the incidence of coronary stent thrombosis in a given study, the larger the net clinical 
benefit from a PR-tailored strategy.15 Finally, the ADAPT-DES registry of patients undergoing 
PCI showed that high PR was predictive of stent thrombosis mostly in ACS patients, but 
there was no interaction reported between PR and the presence of an ACS at inclusion.16 
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5 
This information suggests the hypothesis that high PR might be more relevant in high-risk 
populations, but convincing data at the individual level are lacking. To date, the only meta-
analysis on individual patient data performed on 6 studies totalling 3,059 patients assessed 
with the VerifyNow P2Y12 assay did not explore this hypothesis.17 Similarly, one of the 
largest and more recent meta-analysis on 8 studies and 4817 patients did not explore this 
interaction due to the lack of individual data.18 To further investigate this interaction on a 
larger population we performed a collaborative meta-analysis of individual patient data and 
focused on the interaction between relevant vascular risk factors and PR, assessed with 
ADP induced light transmission aggregometry (LTA), in order to better define the risk of 
MACE.  ADP-induced LTA is the assay upon which all P2Y12 receptor inhibitors have been 
developed, thus supporting its use in the present meta-analysis. In addition, among several 
available assays to evaluate PR, LTA is the historical gold standard with which most platelet 
function assays were compared.   
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Methods 
Data sources 
Literature review, confined to articles in English,19 was based on electronic databases 
(Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials) and 
abstracts from major international meetings held from 2010–2013 (ISTH, AHA, ACC, ESC). 
A free-text search was conducted using an ‘ADP’ and ‘aggregation’ and ‘clopidogrel’ key-
word combination. Articles were selected on the basis of abstracts, before examination of the 
full text. Reference lists of selected articles were also hand-searched to identify additional 
relevant reports. R viewers (JLR and PF) were not blinded to the journal, authors or 
institutions in the publications as this has been shown to be unnecessary.20 The electronic 
database search was last updated on 31 July, 2013. 
 
Study selection 
Selected studies met the following criteria: (a) patients were treated with clopidogrel and had 
symptomatic atherothrombosis (clinical signs related to vascular atherothrombotic lesions); 
(b) pharmacodynamic response to clopidogrel was evaluated using the maximal aggregation 
value from LTA on platelet-rich plasma with 20, 10, or 5 µM ADP as an agonist; (c) LTA was 
performed remote from platelet function interfering drugs such as GpIIb/IIIa inhibitors; (d) 
patients were prospectively monitored for MACE for at least 30 days, defined using at least 
one of the following items: acute coronary syndrome (unstable angina, myocardial infarction 
with/without ST segment elevation), ischemic stroke (acute neurological deficit due to a 
cerebral infarction), and vascular death; (e) studies involved either a prospective cohort or a 
randomised therapeutic trial, but one in which treatment was allocated independently of the 
response to clopidogrel. When studies were suspected of including the same patients, the 
authors were asked to provide data from the largest possible number of independent patients. 
The flow of references through the review process is shown in Figure 1.  
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Data extraction 
The corresponding authors or principal investigators of eligible studies were contacted and 
asked to participate in the CLOpidogrel and Vascular ISchemic events – Individual Patient 
Data (CLOVIS-IPD) meta-analysis group. Investigators provided individual data on: the 
qualifying cardiovascular condition and clinical setting at inclusion (ACS or stable disease); 
MACE and date of occurrence during follow-up; platelet reactivity (PR) with ADP 20, 10, 
and/or 5 µM and its timing relative to loading dose of clopidogrel; age, gender, height, and 
weight; current smoking status, diabetes, hypercholesterolemia, and hypertension; left 
ventricular ejection fraction; platelet count; PCI; use of GpIIb/IIIa inhibitors and timing; 
concomitant medications; and bleeding events and timing during follow-up. Data were 
checked for completeness and consistency with published reports. Any discrepancies were 
resolved with the corresponding authors. After format harmonisation, data were compiled for 
statistical analysis. All studies were approved by their respective institutional review boards.  
 
Quality assessment of studies  
A new quality assessment tool for prognostic studies called PROBAST (see 
Acknowledgements) was used to estimate risks of bias and concerns about applicability. As 
PROBAST is not customised for meta-analyses of individual patient data, items were 
adapted accordingly. Based on the present study’s list of relevant criteria, risks of bias, and 
concerns about applicability are rated as low, unclear, or high. Supplemental Figure 1 shows 
the list of criteria. 
 
Primary outcomes and measures 
The primary clinical outcome was the occurrence of MACE, as defined above (see Study 
selection (d)). The primary biological outcome was maximal aggregation with 20 µM ADP, as 
it is a better concentration for analysing the effects of clopidogrel than lower ones. PR was 
categorised in three strata. The higher cut-offs were selected on the basis of previously 
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8 
published cut-offs (59% to 64% for 20 µM ADP, and 43% to 46% for 5 µM ADP),21 and to 
keep relatively balanced numbers of patients in each PR categories. Three pre-specified 
categories allowed a better description of the dose-dependent effects of PR on the risk of 
MACE compared to the usual dichotomic high and low PR categorization. Three categories 
were also chosen to better parallel the analysis with a therapeutic PR window that has been 
associated with optimal net clinical benefit.22  A surrogate for the level of cardiovascular risk 
was defined as the number of factors with homogeneous definitions across studies, and 
these were markers of MACE in the meta-analysis. The factors were selected from among 
age, diabetes, hyp rtension, smoking, hypercholesterolemia, and the presence of an ACS at 
inclusion (as defined in study selection (d)), and were all provided at the time of inclusion and 
PR testing.  
 
Statistical analysis  
MACE-free survival curves were derived from individual patient data using the Kaplan-Meier 
estimator; curves were compared using log-rank tests stratified by study. Associations 
between conventional risk factors, PR strata, and risk of MACE were analysed using 
multivariate, mixed-effect Cox models. The amount of heterogeneity was assessed by the 
size of the random effects (Tau2) which is an estimate of the between study variability.23 The 
presence of heterogeneity was tested by comparing models with and without random effects 
(likelihood ratio test). The interactions between the level of risk and PR strata were tested. 
MACE-free survival according to PR, as a continuous variable, was assessed using the R 
package prodlim using the symmetrical nearest neighbourhoods method.24 Sensitivity 
analyses were conducted to check the robustness of the findings with respect to: the risks of 
bias and concerns about the applicability of studies; the definition of MACE, including target 
vessel revascularisation or PCI at inclusion, and; the influence of a given specific study. The 
net reclassification index (NRI) for survival data25 was computed to quantify the contribution 
of PR testing for the prediction of the 6-month risk of MACE in patients with increasing 
numbers of traditional risk factors. The event and non-event continuous NRIs were reported. 
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9 
Potential publication bias was checked for. P-values below 0.05 were considered significant 
and all tests were two-sided. Published guidelines for meta-analysis of observational studies 
in epidemiology (MOOSE) and their reporting26 were followed. Details on statistical methods 
are given in the online data supplement.  
 
Results 
Characteristics of included studies 
The Figure 1 flow-chart details how 13 of 20 qualifying studies were included, totalling 6,478 
patients.8 27-38 Tabl  1 shows their characteristics. Data on body mass index, concomitant 
medications, left ventricular ejection fraction, or the occurrence of target and non-target 
vessel revascularisation during follow-up were only available in some studies. All studies 
provided individual data allowing a homogeneous definition of MACE, current smoking status, 
ACS, diabetes (fasting plasma glucose ≥ 7.0 mmol/l, 2-h plasma glucose ≥ 11.1 mmol/l after 
75g oral glucose load or background th rapy for diabetes), and hypertension (systolic blood 
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or a documented history of 
hypertension). Hypercholesterolemia was not defined in a homogeneous fashion across 
studies and plasma LDL-cholesterol levels were not available for more than 2,000 patients. 
Overall, risks of bias and concerns about applicability were low (online data supplement 
further details study characteristics, bias, and applicability). Information on bleeding was 
limited to five studies, with only 67 major and 20 moderate/minor bleedings.  
 
MACE and level of risk  
Overall, 421 MACE occurred in 6,478 patients (6.5%), the majority being ACS (n = 383). 
There were 83 stent thromboses, including 79 definite or probable and four possible ones, all 
included in the composite outcome of MACE.  The MACE-free survival rate across the 
different studies at the end of follow-up ranged from 77.4% to 97.3%. In a multivariate 
analysis, four factors were found relevant to determining patients’ levels of risk: age greater 
than 75 years, diabetes, ACS at inclusion, and hypertension (Table 2). The number of these 
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10 
factors was used as a surrogate for the individual risk of MACE. Patients with none of these 
factors were classified ‘low-risk’, patients with one factor ‘intermediate-risk’, and patients with 
two or more factors ‘high-risk’ (global p-value <0.0001 for the trend). 
 
MACE and PR  
Nine studies (n = 4,438 patients) performed LTA using 20 µM ADP, four studies (n = 2,144 
patients) used 10 µM ADP, and eight studies (n = 3,317 patients) used 5 µM ADP. Figure 2 
shows the MACE-free survival curves by category of ADP concentration. Risk of MACE 
increased significantly with PR with 20 µM ADP, 10 µM ADP, and 5 µM ADP.  
With adjustment, high PR was still significantly associated with an increased risk of MACE 
(Table 3). However, for PR evaluated using 10 µM ADP, risk only increased for the highest 
PR category, corresponding to LTA values greater than 60%.  
 
Interaction between risk level and PR for the outcome of MACE 
Platelet reactivity assessed with 20 µM ADP  
Patients with none of the four risk factors showed no significantly increased risk associated 
with PR, while for patients with one risk factor only, the higher strata of PR was associated 
with an increased risk of MACE. Patients with two or more risk factors showed an increased 
risk of MACE for both the medium and higher strata of PR. (Figure 3). In a Cox model, the 
interaction between PR strata and the risk level was statistically significant (p=0.04). The 
corresponding hazard ratios (HRs) are shown in Figure 3. Heterogeneity was not detected 
for the overall interaction (p=0.81), as well as when it was restricted to each risk level 
category (intermediate versus low risk level, p=0.45, and high versus low risk level, p=0.90). 
Additional results on heterogeneity are provided in the supplemental material. Figure 4A 
shows that PR, when analysed in a continuous fashion, barely affects the risk of MACE at 6 
months in patients with no risk factors:  the risk is close to 2% at six months, irrespective of 
the level of platelet reactivity. Conversely, patients with one risk factor and an overall 4.1% 
risk of MACE at six months have in fact a 2% risk of MACE when they have a low PR, or a 
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6% risk of MACE when they have a high PR (Figure 4B). Similarly, patients with two or more 
risk factors and an overall 6% risk of MACE at six months can indeed have a 2% risk of 
MACE when they have a low PR (Figure 4C). The reclassification of the 6-month risk of 
MACE, according to the three categories of platelet reactivity, in patients with no, one and 
tw  or more risk factors, is shown in Table 4. Overall, PR allowed the reclassification of 44% 
of the total population (1837/4193 patients) included in a 6-month follow-up to a different 
level, mostly in patients originally identified as intermediate or high risk on the basis of the 
number of risk factors only. In patients experiencing MACE in the first 6 months of follow-up, 
the risk predicted by the combination of PR and risk factors was on average increased 
compared with the risk predicted from risk factors only: the continuous event net 
reclassification index (NRI) was 0.39 (95%CI 0.23 to 0.62). Conversely, in patients free of 
MACE at 6 months, the measure of PR did not modify the predicted risk: the continuous non-
event NRI was 0.01 (95%CI -0.16 to 0.09). The overall NRI was 0.39 (95%CI 0.22 to 0.57).  
 
Platelet reactivity assessed with 10 µM ADP  
A total of only five low-risk patients in four studies performing 10 µM ADP LTA to assess PR 
precluded an analysis of this low-risk group. Furthermore, the surrogate for risk level failed to 
demonstrate an association with the observed risk of MACE in these studies. Figure 4B 
shows that the risk of MACE increased in both intermediate- and high-risk patients for PR 
values above 40%, without any obvious relation with the level of risk.  
 
Platelet reactivity assessed with 5 µM ADP  
The direction of interaction between PR using 5 µM ADP and the risk level was similar to that 
observed for PR using 20 µM ADP, even though overall interaction did not reach the 
significance level (p=0.17). Of note there were 980 fewer patients in the studies performing 5 
µM ADP than in those using 20 µM ADP. The increased risk of MACE as PR increases is 
indeed similar for intermediate- and high-risk patients; for low-risk patients PR is not 
associated with a MACE outcome (online data supplement). Heterogeneity was not detected 
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for the overall interaction (p=0.19). Figure 4C shows that the risk of MACE was unaffected by 
PR in low-risk patients while it increased for PR values above 30% in intermediate-risk 
patients and for PR values above 10%–20% in high-risk patients. 
 
Sensitivity analyses 
Sensitivity analyses were performed for PR using 20 µM ADP to assess: the robustness of 
the association between PR and risk of MACE and its interaction with the level of 
cardiovascular risk; the robustness of the results in the population of PCI patients and when 
target vessel revascularisation is added to the composite outcome. All analyses showed that 
the sizes of the effects remained similar, and whilst in some instances the statistical 
significance of the interactions could be lost, there was no impact on their magnitudes 
(supplemental Tables 1 and 2). Notably, when PR was categorised in quartiles (20 µM ADP 
maximal aggregation quartiles = 0%–38.1%, 38.2%–51.3%. 51.4%–63.0%, 63.1%–100%) 
the interaction between PR and the number of risk factors remained significant (p=0.01). 
When restricted to the population of 3,564 patients treated with PCI and tested using 20 µM 
ADP the interaction was of similar magnitude but no longer significant (supplemental Table3). 
 
Publication and availability biases 
A check for potential publication bias was made for PR using 20 µM ADP, on which the main 
analyses were performed. A funnel plot was obtained by representing the HR of PR using 20 
µM ADP and the standard error, assessed in each separate study (supplemental Figure 4). 
Two studies with a negative association between PR using 20 µM ADP and the risk of MACE 
(with small sample sizes) were detected as missing using the ‘trim and fill’ method for making 
the funnel plot symmetrical. When these missing studies were added, the pooled HR was not 
significantly modified. These findings suggested that the publication bias in our meta-analysis 
was minor.  
Seven qualifying studies could not provide individual patient data. It is of note that in five of 
these, the relation between clopidogrel non-response and ischemic events was not a study 
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13 
objective (pharmacokinetic-pharmacodynamic studies or randomised trials of different 
clopidogrel loading doses). The two remaining studies (n = 101 and 111 patients) were 
specifically interested in the prognostic value of PR for MACE.  
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Discussion 
In the present meta-analysis of individual patient data conducted in clopidogrel-treated 
patients we demonstrated that the association between PR and the risk of MACE depended 
str ngly on the level of cardiovascular risk. When using 20 µM ADP, the most commonly 
used concentration in LTA, the risk of MACE associated with PR increased with the level of 
cardiovascular risk. Indeed, PR did not affect the risk of MACE in patients presenting no risk 
factors, however it gradually increased the risk of MACE as the number of cardiovascular risk 
factors increased, reaching a 3.7 times greater risk in high-risk patients with a high PR. The 
measure of PR with 20 µM ADP, in addition to risk factors, modified the interpretation of the 
6-month risk of MACE in 44% of patients, mainly in patients with at least one risk factor. 
Interestingly, smoking and hypercholesterolemia were not associated with the outcome of 
MACE and were not included in the analysis of the interaction between PR and risk factors. 
In randomised controlled trials, the ben fit of clopidogrel in reducing the incidence of MACE 
is primarily seen in smokers, with little benefit to non-smokers.39 With regard to the cohort 
studies of clopidogrel-treated patients included in this meta-analysis, this differential effect 
suggests that the increased risk of MACE related to smoking is offset by the benefit 
clopidogrel provides to smokers; it thereby weakens any possible analysis of the interaction 
between smoking and PR for outcomes of MACE. Regarding hypercholesterolemia, this 
conventional risk factor is likely to be confounded by indications for statin treatment. Indeed, 
in the ADAPT-DES registry16 hyperlipidemia was protective against mortality with a HR=0.60 
(0.41–0.86) and was not prognostic of MACE in post-ACS patients with optimal medical 
therapy.40 In addition, hypercholesterolemia was not homogeneously defined across the 
studies in the present meta-analysis and other markers, such as plasma LDL-cholesterol 
levels, were not widely available.  
When PR was evaluated using 5 µM ADP, its interaction with the level of cardiovascular risk 
for the prediction of MACE was of a similar magnitude, although non-significant. These 
findings may reflect the lower number of patients available in studies using 5 µM ADP, and a 
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corresponding loss of power. Moreover, it was previously shown that ADP-induced platelet 
aggregation in citrated plasma was dependent on the artifactual generation of TxA2 that was 
modulated by aspirin, at least at lower ADP concentrations.41 This may be associated with an 
additional background noise in which the interaction between the identified risk factors and 
PR to predict MACE is blurred, as seen with the lowest concentrations of ADP. Only four of 
the studies analysed used 10 µM ADP, and two of these had a follow-up limited to 30 days; 
with only 124 MACEs during follow-up, this accounts for a limitation in power to reliably study 
interactions. Which laboratory assay and which platelet agonist concentration are best suited 
for the clinical evaluation of platelet function is the matter of some debate. ADP-induced LTA 
is highly reproducible within a given laboratory, but its lack of standardisation across studies 
may have slightly weakened the positive findings or lower the level of significance for the 
interactions found in the present meta-analysis. Of note, the present meta-analysis does not 
aim to promote the use of LTA to tailor antiplatelet therapy but it rather relied on a historical 
gold standard in platelet function testing to evidence an interaction with 
patients’characteristics that should be considered for a tailored approach.  The point-of care 
VerifyNow P2Y12 assay, used in several intervention trials, correlates well with ADP-induced 
LTA42 43 and we speculate that the main findings of the present meta-analysis would have 
been similar, had PR been evaluated using the VerifyNow P2Y12 assay.  
 Several intervention trials have compared conventional clopidogrel treatment to an 
antiplatelet strategy tailored according to PR. Early, small randomised trials11 12 that utilised 
vasodilator-stimulated phosphoprotein phosphorylation level measurement to indicate P2Y12 
receptor reactivity, showed a protective effect for repeat 600 mg clopidogrel loading doses in 
ACS patients prior to PCI. However, recent larger trials utilising the VerifyNow P2Y12 assay 
were negative. Indeed, the GRAVITAS13 and ARCTIC14 studies failed to show the benefit of a 
PR-tailored antiplatelet strategy after PCI. Various limitations of these trials were addressed 
in a recent consensus publication.22 The event rate of the GRAVITAS study was low 
compared to the one used for power calculation, and the antiplatelet effect of the high-dose 
regimen may have been suboptimal as it reduced the prevalence of high PR by only 22%. 
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Similarly, the ARTIC study population was also at a low absolute risk of subsequent 
cardiovascular events because the prevalence of ACS patients was low, and the composite 
endpoint also included other events that may not be related to platelet function. The 
interaction of PR and the number of risk factors, as identified in the present meta-analysis, 
substantiates the hypothesis that the risk associated with high PR was not clinically relevant 
in low-risk patients, and that any measure aiming to lower PR is unlikely to lead to a 
beneficial reduction of MACE for these low-risk patients. Based on these observations we 
speculate that higher risk patients are more likely to benefit from a therapy tailored to their 
initial PR. This may explain why early interventions designed to efficiently blunt high PR in 
ACS patients with multiple conventional risk factors translated into a reduction of MACE.11 12 
22.  
In the current new antiplatelet era, prasugrel and ticagrelor have a major part to play in the 
management of ACS, leaving clopidogrel as an alternative for patients with high bleeding risk. 
However, a recent cost-effectiveness analysis for six European perspectives showed that the 
universal use of newer P2Y12 inhibitors for ACS patients is probably not as cost-effective as 
strategies based on PR.44 It should also be kept in mind that ticagrelor and prasugrel 
increase the risk of bleeding and that a therapeutic medium-PR window is associated with 
optimal net clinical benefit.22 The net benefits of newer P2Y12 inhibitors could also probably 
be improved not only by testing for PR, but also by incorporating patient risk levels in the 
decision-making process. Although ongoing trials on tailored P2Y12 strategies, including 
TROPICAL-ACS (ClinicalTrials.gov identifier: NCT01959451)  and ANTARCTIC45 partly 
include this concept of risk levels, further efforts in this direction are needed.  
This meta-analysis has several strengths, such as the good overall quality of the studies 
included, as assessed using a quality tool specifically adapted to prognostic studies. The 
availability of individual patient data allowed a reliable evaluation of the risk associated with 
PR and of the interaction with vascular risk factors. Readily available risk factors relevant to a 
secondary prevention population were thus identified. The consistency of results across the 
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different ADP concentrations used in the different studies to assess PR, as well as the 
sensitivity analyses, indicated that the results were robust.  
Despite the advantages related to the availability of individual patient data, this meta-analysis 
also had some limitations, including a low proportion of women (25%). This did not allow a 
stratification of the analyses by gender, as is usually the case in risk assessment tools such 
the European SCORE or the Framingham risk score. Indeed, in these latter scores gender is 
not considered as one of traditional risk factors, but is rather presented in separate charts for 
women and men. There were incomplete data on concomitant medications or other relevant 
risk factors such as the left ventricular ejection fraction, cholesterol levels or renal 
insufficiency. Finally, information on bleeding was limited to five studies and a low number of 
events, thus precluding a reliable analysis of bleeding events and their relation to PR.      
In conclusion, high PR in patients on clopidogrel is associated with an increased risk of 
MACE in patients with vascular risk factors, but not in low-risk patients. These findings 
suggest that trials on tailored PR treatment strategies should be primarily stratified on the 
individual vascular risk factors in order to assess a truly personalized approach.  
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What this paper adds 
 
What is already known on this subject 
Prior meta-analyses have shown an association between high on-clopidogrel platelet 
reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, data 
are heterogeneous and large intervention trials on PR-tailored treatments have been neutral, 
possibly owing to the inclusion of patients at low cardiovascular risk. The role and usefulness 
of PR with regard to levels of cardiovascular risk are unclear and may explain these 
discrepancies.   
What this study adds 
• The magnitude of the association between PR and MACE risk is strongly dependant 
on the level of cardiovascular risk faced by patients suggesting that trials on tailored 
PR treatment strategies should be primarily stratified on the individual vascular risk 
and clinical setting.  
• This study suggests that medical policies edicted around the concept of personalized 
medicine should not be restricted to a single biological phenotype or single nucleotide 
variant but should also emphasize the role of individual clinical risk factors.  
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Table 1. Main characteristics of published studies  
 
Study 
Years of 
publication 
Patients 
(n) 
Age 
(y) 
Male 
(%) 
Diabetics 
(%) 
Smokers 
(%) 
Hyper-
tension 
(%) 
Hypercholes-
terolemia 
(%) 
ACS at 
inclusion 
(%) 
PCI  
(%) 
GpIIb/IIIa 
inhibitor 
(%) 
Follow-up  
(months)* 
ADP 
(µM) 
Campo et al.
27
 2006 70 64±13 69 19 37 63 34 100 100 100 10 (15) 5, 20 
Hochholzer et al.
28
 2006 765 66±9 78 24 11 82 92 0 100 0 12 (12) 5, 20 
Angiolillo et al.
29
 2007 173 67±9 65 100 13 65 68 0 0 0 24 (36) 20 
Cuisset et al.
30
 2007 190 65±12 76 33 48 58 53 87.4 100 14.7 1 (1) 10, 20 
Geisler et al.
31
 2008 1,092 67±11 74 33 39 80 59 51.7 100 7.7 1 (1) 20 
Gurbel et al.
32
 2008 297 65±12 65 41 55 74 82 0 100 42 24 (24) 5, 20 
Cuisset et al.
33
 2009 598 65±12 78 35 39 56 55 100 100 9.9 1 (1) 10 
Yong et al.
34
 2009 248 63±12 71 22 27 53 52 100 55 39.7 6 (21) 5, 10, 20 
Breet et al.
35
 2010 1,069 64±11 75 81 11 77 80 0 100 7.0 12 (12) 5, 20 
Marcucci et al.
36
 2010 1,108 69±10 75 24 23 66 55 100 100 26.0 12 (12) 10 
Beigel et al.
37
 2011 174 59±12 83 27 41 51 45 100 100 - 6 (6) 5 
Aradi et al.
38
 2012 160 62±9 63 38 36 84 50 0 100 0 12 (12) 5 
Reny et al.
8
 2012 534 62±12 82 21 20 56 63 0 0 0 32 (50) 5, 20 
Age, mean ± standard deviation; CAD, coronary artery disease; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; ADP, 
adenosine diphospate concentration used for the evaluation of platelet reactivity  
* Median (maximum) 
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Table 2: Multivariate analysis to assess the associations between the risk factors and the composite outcome of MACE. This analysis was 
conducted on the patients of the 13 studies of the meta-analysis (n=6,256 after exclusion of missing data). MACE were observed in 412 
patients. Hazard ratios (HR) greater than one show an increased risk of MACE in patients having the corresponding risk factor.   
 
Factors collected in studies Adjusted HR [95% CI] p Level of risk of MACE * HR [95% CI] p 
   Current smoking status 0.92 [0.71;1.18] 0.50     Low risk (n=579) 1 
    Age (> 75) 1.56 [1.25;1.95] <0.0001     Intermediate risk (n=2444) 1.61 [1.05;2.45] 0.03 
   Diabetes 1.58 [1.27;1.96] <0.0001     High risk (n=3435) 2.58 [1.69;3.94] <0.0001 
   Hypercholesterolemia 0.86 [0.69;1.06] 0.15 
      Hypertension 1.23 [0.98;1.54] 0.07 
      ACS at inclusion 2.00 [1.27;3.16] 0.003 
      Gender (Male) 1.11 [0.89;1.40] 0.35     
*: a surrogate for the level of risk was defined as the number of risk factors (among age, diabetes, hypertension, and ACS at inclusion): low risk 
for no risk factor, intermediate risk for one risk factor and high risk for two or more risk factors). 
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Table 3: Associations between the ADP categories and the composite outcome of MACE with adjustment on the factors collected in the studies 
of the meta-analysis (factors shown in Table 2).  
ADP 20 µM ADP 10 µM ADP 5 µM 
N N N 
Studies 9 
 
4 
 
8 
 
Events 287 
 
124 
 
229 
 
Patients (after exclusion of missing data) 4,140 
 
2,077 
 
3,160 
 
 
HR [95% CI] p HR [95% CI] p HR [95% CI] p 
ADP 
 
0.0003 
 
0.03 
 
0.02 
     Lower category * 1 
 
1 
 
1 
 
     Intermediate category * 1.85 [1.26;2.73] 0.002 1.31 [0.79;2.17] 0.30 1.79 [1.02;3.14] 0.04 
     Higher category * 2.91 [1.78;4.74] <0.0001 2.61 [1.64;4.16] <0.0001 2.79 [1.50;5.22] 0.001 
* Categories for ADP 20 and 10 µM are 0%-40%, 41%-60%, 61%-100%,  
and for ADP 5 µM are 0%-30%, 31%-50%, 51%-100% 
HR, Hazard Ratio; CI, Confidence Interval 
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Table 4:  Reclassification of the 6-month risk of MACE when the individual risk was predicted from platelet reactivity measured by 20µM ADP in 
addition to risk factors. The predicted risk was stratified in three levels (low: ≤3%, intermediate: >3% and ≤5%, high: >5%) in agreement with the 
6-month risk observed in patients with none, one and two or more risk factors (2.3%, 4.1% and 6.2% respectively). Patients were stratified 
according to their number of risk factors and to the level of the predicted risk. The numbers of patients and, in brackets, the corresponding 
observed 6-month risk of MACE in each stratum.       
   
 
 
 
Risk predicted by the combination of risk factors and platelet 
reactivity measured by 20µM ADP    
  
Low risk  
(≤3%)  
Intermediate risk  
(>3% and ≤5%)  
High risk  
(>5%) Total 
Risk predicted by 
the number of risk 
factors only 
Low risk  - no risk factor 524 * (2.4% **) 26 * 0 * 550 * (2.3% **) 
Intermediate risk - one risk factor 625 * (2.1% **) 576 * (3.7% **) 622 * (6.3% **) 1823 * (4.1% **) 
High risk - two or more risk factors 102 * (0.0% **) 462 * (3.0% **) 1256 * (7.6% **) 1820 * (6.2% **) 
Total 1251 * (2.1% **) 1064 * (3.4% **) 1878 * (7.1% **) 4193 * (4.7% **) 
*: number of patients  
**: observed 6-month risk of MACE  
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Figure Legends 
 
Figure 1: Flow chart of the meta-analysis  
 
Figure 2: Kaplan-Meier survival curve for the occurrence of MACE  
 
Figure 3: Association between platelet reactivity and the occurrence of MACE 
according to the level of risk 
Low-risk patients have none of the risk factors (among age > 75 years, acute coronary 
syndrome at inclusion, diabetes, and hypertension), intermediate-risk patients have one risk 
factor and high-risk patients have two or more risk factors. PR was assessed with 20 µM 
ADP LTA.  
 
Figure 4: 6-month risk of MACE according to platelet reactivity in the different risk 
groups. The dashed line represents the overall risk, ignoring platelet reactivity and the black 
line shows the risk according to the platelet reactivity assessed with 20 µM ADP LTA, in 
patients with no risk factors (A), one risk factor (B) and two or more risk factors (C).  
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Figure 1 
 
 
  
9 duplicate data
29 excluded studies (non-prospective, no 
clinical endpoint, no ADP aggregation, non 
english)
7 excluded studies (5 not responding to 
requests, 2 refusals; not providing data for a 
total of 557 patients). 
1,995 identified references
58 full-text  articles 
assessed for eligibility 
13  included studies 
totaling 6,478 patients
1,937 excluded references (duplicates between 
databases, animal, no clinical endpoint, non-
prospective, no ADP aggregation)
20 qualifying studies
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Figure 2 
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Figure 3  
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Figure 4  
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Supplemental material 
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of 
major adverse cardiovascular events in patients on clopidogrel:  
Systematic review and collaborative meta-analysis of individual patient data 
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Detailed statistical analysis   
 
Complementary characteristics of studies, risks of bias, and concerns   
regarding applicability 
 
Supplemental Figure 1. Criteria to assess risks of bias and concerns about 
applicability  
 
Supplemental Figure 2. Result of the assessment by domains for risk of bias and   
concerns about applicability 
 
Cox models and assumption of proportionality of hazards  
 
Complementary results on heterogeneity  
Detailed results on studies using 5 µM ADP to assess platelet reactivity  
 
Supplemental Figure 3. Interaction between 5 µM ADP LTA values and the level of 
risk  
 
Sensitivity analyses  
 
Supplemental Table 1. Sensitivity analysis for the association between PR using   
20 µM ADP and risk of MACE (leave-one-out procedure) 
 
Supplemental Table 2. Sensitivity analysis for the modification of the   
association between PR, assessed using 20 µM ADP and risk of MACE 
 
Supplemental Table 3. Sensitivity analysis in patients with PCI at inclusion and when 
  
target vessel revascularisation (TVR) is included in the composite outcome 
 
Supplemental Figure 4. Funnel plot for detection of a potential publication bias  
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Detailed statistical analysis  
MACE-free survival curves were obtained using the Kaplan-Meier estimator and by pooling 
data from studies. Comparisons between subgroups of PR with ADP 20, 10, and 5 µM were 
performed using log-rank tests stratified on the studies. A surrogate of the individual level of 
risk of MACE was obtained by identifying the factors associated with the MACE outcome in a 
multivariate mixed-effect Cox model and by counting the number of these factors. The tested 
factors were the traditional risk factors (age, hypercholesterolemia, diabetes, hypertension, 
smoking, and acut  ischemic event at inclusion). Other risk factors, such as body mass index 
or family history, were available in only a limited number of studies and were not included as 
covariates. The between-study variability in the baseline hazard was accounted for by a 
random coefficient. This analysis was conducted on the whole sample with the R package 
‘coxme’.46 47  
In subsets of studies reporting PR evaluated using 20 µM, 10 µM, and 5 µM ADP, 
associations between PR, expressed in categories (low, intermediate, high PR) and the risk 
of MACE, was analysed using mixed-effect Cox models with adjustment for traditional risk 
factors. The between-study variability was accounted for by a random coefficient for the 
baseline hazard and for each category of PR. The surrogate for the level of MACE risk 
(number of risk factors) was explored as a modifier of the association between PR and the 
risk of MACE: the interaction term was tested in a mixed-effect Cox model. The HRs were 
reported for intermediate and high PR categories, taking the category low as the reference 
and according it to the number of risk factors. To better describe the modification of the 
associations between PR and the risk of MACE, the MACE-free survival rates in patients at 
low-, intermediate-, and high-risk were assessed according to PR, as continuous variables. 
This analysis was conducted using the R package prodlim, using the symmetrical nearest 
neighbourhoods method24. The assumption of the proportionality of hazards was tested for all 
models using Cox models,48 since this procedure was not available for mixed-effect Cox 
models and by plotting the complementary log-log survival against the logarithm of time. 
Sensitivity analyses were conducted to check the robustness of the findings with respect to 
the risks of bias and concerns for applicability of studies, as well as the definition of MACE 
including target vessel revascularisation and the influence of a given specific study (leave-
one-out analysis). A potential publication bias was visually inspected on a funnel plot. The 
‘trim and fill’ method was also applied to detect missing studies (for the funnel plot to be 
symmetric) and to test the sensitivity of the estimate to these missing studies.49  The 
improvement in the assessment of 6-month risk of MACE related to the measure of platelet 
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reactivity was evaluated by using the net reclassification index for survival data [REF 
PENCINA].The event and non-event continuous NRIs were reported. When the continuous 
event NRI is positive, the predicted risk in patients experiencing MACE is more often 
increased than decreased, following the addition of PR  to risk factors than when it involves 
risk factors only. Similarly, when the continuous non-event NRI, the predicted risk in patients 
experiencing MACE is more often decreased than increased when the prediction involves PR 
in addition to risk factors than when it involves risk factors only. To assess the event and 
non-event NRIs, we used the risk assessed according to PR as a continuous variable 
(previously described).   
All analyses were conducted using R version 3.0.1 (R Development Core Team. R: A 
Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for 
Statistical Computing; 2010) and Comprehensive Meta-Analysis Version 2 (Biostat, 
Engelwood, NJ, USA). P-values less than 0.05 were considered significant and all tests were 
two-sided. 
 
Complementary characteristics of studies, risks of bias, and concerns regarding 
applicability 
In several instances, data on covariates were not available. For example, data on the use of 
proton pump inhibitors and statins were not available from eight studies. Aspirin was part of 
the treatment for all patients in ten studies, and was given to 79%, 90%, and 95% of the 
patients in the three remaining studies. All but one study included coronary artery disease 
(CAD) patients exclusively; this last study8 included 85% CAD patients, 10% peripheral 
arterial disease patients, and 5% ischemic stroke patients. PCI was performed on 87% of 
patients. The studies differed markedly with respect to the frequency of diabetes (19%–
100%), smoking (11%–55%), the use of GpIIb/IIIa inhibitors (0%–100%), the ADP 
concentration used for aggregation tests (5–20 µM) to assess PR, and the presence of acute 
ischemia at inclusion (0%–100%). The median follow-up was 12 months, and in all the 
studies the modalities of the follow-up were identical for clopidogrel responders and non-
responders. LTA was most frequently performed using ADP 20 µM.  
Overall risks of bias and concerns about applicability of the studies were low (Figures 1 and 
2). In one study using LTA with ADP 10 µM, MACE was defined as stent thrombosis during a 
30-day follow-up period;33 however, with no specific information on myocardial infarction or 
stroke (as was the case in most of the studies), this lead to a potential high risk of outcome 
bias. In three studies,27 36 38 the risk of outcome bias was unclear because either they did not 
include stroke in the composite outcome of MACE or they did not mention whether 
adjudication of the outcome was performed blinded to PR test results. In another study, using 
LTA using ADP 20 µM, the risk of bias with respect to flow and timing was unclear as 13% of 
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patients had been lost to follow-up.31 The characteristics, PR test results, and treatments of 
these patients were similar to the rest of the cohort. Regarding their applicability, only two 
studies caused concern, because of an exclusively diabetic population in one,29 and because 
of the absence of upper and lower limits to the platelet counts of the patients included in the 
second.38   
  
Page 36 of 53
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 110 of 127Thrombosis and Haemostasis
For Peer Review
Confidential: For Review Only
36 
 
Supplemental Figure 1 Criteria to assess risks of bias and concerns about applicability. Derived from the PROBAST tool available at  
www.systematic-reviews.com/probast  
Risk of bias 
Domains    Criteria 
Patient selection Consecutive 
Inappropriate inclusion or exclusion criteria 
Disease at similar stage (inclusion) 
Predictor ADP LTA and covariates Pre-specified or standard technique used 
ADP LTA done at the same time for all participants 
Vascular risk factors available 
Outcome All items defining MACE available 
MACE diagnosed blinded to ADP test results 
Adjudicating committee blinded to ADP test results 
Same MACE definition for all participants 
ADP test results did not form part of MACE outcome 
Flow and timing All patients included in the analysis 
Lost to follow up  
Clopidogrel was not stopped during follow-up 
All the patients benefited from the same MACE assessment 
Exact date of MACE known  
 
Concerns about applicability 
Domains Criteria 
Patient selection Sample representative of review’s target population 
Predictors Standard definition for covariates 
Outcome Unexpected relative frequency of one or more MACE items 
Differences in the quality of assessment of each MACE item 
The time of assessment of MACE is relevant to the clinical situation 
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Supplemental Figure 2: Result of the assessment by domains for risks of bias and concerns about applicability 
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Cox models and assumption of proportionality of hazards 
For the multivariate Cox model stratified on studies and conducted on the whole sample to 
identify risk factors, the hazards were found to be approximately proportional. The p-value for 
the test on residuals was greater than 0.10 for any factor. A visual inspection of the log minus 
log survival plots did not reveal any major deviation from the proportionality of hazards. 
When PR evaluated using ADP 20 µM was added in the model, the p-values were 0.33 for 
the 41%–60% PR category and 0.28 for the 61%–100% category. When PR evaluated using 
ADP 10 µM was added in the model, the p-values were 0.89 for the 41%–60% PR category 
and 0.63 for the 61%–100% category. When PR evaluated using ADP 5 µM was added in 
the model, the p-values were 0.72 for the 31%–50% PR category and 0.19 for the 51%–
100% category. A visual inspection of the log minus log survival plots revealed that when 
using 10 µM ADP, the survival curves crossed in the first 20 days of follow-up. However, the 
survival in this period was close to one and the cross was not meaningful. In models testing 
the interaction between PR (evaluated using 20 µM ADP and 5 µM ADP) and the number of 
risk factors, p-values for all coefficients were greater than 0.20.  
 
Complementary results on heterogeneity 
The amount of heterogeneity is represented by the variance of the random effects23 
corresponding to the between-study variance (Tau2). Theses variances are reported in the 
following table for the mixed-effects Cox model when PR is evaluated using ADP 20 µM. 
Random effects Tau2 
Intercept 0.112 
PR categories 
    41%–60% 0.000 
    61%–100% 0.324 
Interaction terms 
   ADP category 2 * Intermediate risk level 0.134 
   ADP category 3 * Intermediate risk level 0.086 
   ADP category 2 * High risk level 0.043 
   ADP category 3 * High risk level 0.002 
 
 
Detailed results on studies using ADP 5 µM to assess platelet reactivity 
Similarly to results found using 20 µM ADP, for patients with none of the four risk factors 
described above, there was no increased risk for any of the PR strata (HR=0.74 [0.27;2.01], 
p=0.56 for PR=31%–50%; HR=1.20 [0.42;3.47], p=0.73 for PR=51%–100%). In intermediate 
risk patients (one risk factor), there was an increased risk for both the medium and high 
strata of PR (HR=2.87 [1.40;5.90] and p=0.004 for ADP 5 µM 31%–50%; HR=4.81 
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[2.29;10.10] and p<0.0001 for ADP 5 µM 51%–100%), while in high risk patients (two or 
more risk factors), the direction of the effect was the same but only significant for the high PR 
category (HR=1.73 [0.91;3.28] and p=0.10 for ADP 5 µM 31%–50%; HR=2.84 [1.49;5.43] 
and p=0.002 for ADP 5 µM 51%–100%). Figure 4C, in the main text, describes the influence 
of PR, analysed as a continuous variable, on the two-year risk of MACE for the different 
patient risk levels. In low-risk patients, the MACE-free survival fluctuates between 90% and 
95% with no pattern of decreased survival with higher PR. Intermediate risk patients have a 
reduced MACE-free survival corresponding to an increased risk of MACE for PR values 
above 30%, while the risk of MACE in high-risk patients increases earlier (for PR values 
above 20%). 
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Supplemental Figure 3. Interaction between 5 µM ADP LTA values and the level of risk 
Low-risk patients have none of the risk factors (among age > 75 years, acute coronary 
syndrome at inclusion, diabetes, and hypertension), intermediate-risk patients have one risk 
factor and high-risk patients have two or more risk factors.   
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Sensitivity analyses 
Sensitivity analyses were performed for PR using ADP 20 µM. A leave-one-out approach 
was applied to check the robustness of the association between PR using ADP 20 µM and 
risk of MACE. Whichever study was removed, the association remained significant. The HR 
for the intermediate category of maximal aggregation using ADP 20 µM (41%–60%) ranged 
from 1.64 (when Gurbel et al.’s study was removed) to 2.04 (when Angiolillo et al.’s study 
was removed). The HR for the higher category of maximal aggregation values (61%–100%) 
ranged from 2.34 (when Gurbel et al.’s study was removed) to 3.29 (when Hochholzer et al.’s 
study was removed). Thus the association detected in the meta-analyses was not caused by 
any single study (Table1). 
The leave-one-out approach was also applied to evaluate the robustness of the interaction 
between the number of risk factors and the level of PR in predicting MACE outcomes. The 
interaction remained at the same magnitude, but depending on which study was removed it 
was sometimes no longer significant (Table 1). This was most marked when Reny et al.’s 
study was removed, leading to a p-value of 0.22 for that interaction. In this particular case the 
magnitude of the non-significant interaction remained the same (Table 2). 
In the studies evaluating PR using ADP 20 µM, two studies had an unclear risk of bias: 
Geisler et al.’s study, in the domain of ‘flow and timing’ due to patients lost to follow-up;31 and 
Campo et al.’s study, because adjudication of the outcome was not stated as blinded to the 
PR test results, and because stroke and vascular death were not part of the composite 
MACE outcome.27 When these two studies were removed, the results on the interaction with 
risk factors were similar (Table 2). There were unclear concerns about applicability of 
Angiolillo et al.’s study as it included diabetic patients exclusively.29 Removing this study did 
not affect the interaction with risk factors.  
For the main analysis, target vessel revascularisation (TVR) was not included in the 
composite MACE outcome; however, four studies had TVR information available. A re-
analysis of data, restricted to these four studies and comprising 1,066 patients, was 
performed with a definition of MACE including TVR (n=160). The results were similar to those 
obtained when TVR was not included in the composite MACE outcome: the adjusted HRs 
were 2.92 [1.55;5.51] (p=0.0009) and 4.98 [1.72;14.43] (p=0.003) for the intermediate and 
high categories of PR, respectively. When restricted to the population of 3,564 patients 
treated with PCI and tested using 20 µM ADP, the interaction was of similar magnitude but 
no longer significant (Table 3). Similarly, the interactions with the number of risk factors 
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(Table 3) remained of the same magnitude (compared to the main analysis of nine studies on 
4,438 patients), but were no longer significant (p=0.25).  
The robustness of the findings with regard of the choice of cut-offs for PR evaluated using 
ADP 20 µM was checked. Categories of PR were determined by the quartile of PR: 0%–
38.1%, 38.2%–51.3%, 51.4%–63.0%, 63.1–100%. In low-risk patients (no risk factors), the 
HRs for categories 38.2%–51.3%, 51.4%–63.0%, and 63.1–100% were respectively 0.45 
[0.12;1.68] (p=0.23), 0.88 [0.29;2.71] (p=0.82), and 1.98 [0.61;6.48] (p=0.24). In 
intermediate-risk patients (one risk factor), the HRs were 1.33 [0.64;2.72] (p=0.44), 1.54 
[0.77;3.09] (p=0.22), and 4.73 [2.17;10.31] (p<0.0001). In high-risk patients (two or more risk 
factors), the HRs were 2.64 [1.35;5.17] (p=0.005), 3.58 [1.90;6.75] (p<0.0001), and 4.21 
[1.96;9.05] (p=0.0002). The interaction between the level of cardiovascular risk and PR was 
statistically significant (p=0.01).  
An additional sensitivity analysis was carried out to check the robustness of the main findings 
with a different categorizat on of the level of risk. Alternate choices were restricted for 
different reasons : i) the increase in the risk of MACE is aleardy present in patients with one 
risk factor compared to those with none (HR=1.61 [1.05;2.45], p=0.03, as shown in table 2 of 
the manuscript) thus precluding the grouping of patients with 0 or 1 risk factor; ii) patients 
with 4 risk factors had the highest risk of MACE. However, the size of this sub-group (n=173) 
was much too small to analyze it as a single category of risk level. We therefore performed a 
sensitivity analysis with four risk levels : first level = 0 risk factor, second level = 1 risk factor, 
third level = 2 risk factors, fourth levels = 3 or 4 risk factors. The magnitude of the interaction 
between risk level and PR level was similar between this categorization with four risk levels 
and the categorization with three risk levels shown in the manuscript. However the 
interaction term was not significant with this new categorization (p=0.11 from the mixed effect 
Cox model). This can logically be explained by the loss of power due to the higher number of 
parameters involved with the additional risk category. Detailed results are shown in the 
tables below 
 
Number of patients according to the number of risk factors in studies with PR measured by 
20µM ADP, 10µM ADP and 5µM ADP (after exclusion of patients with missing data for PR). 
  20µΜ ADP 10µΜ ADP 5µΜ ADP 
No RF 554 5 519 
1 RF 1874 520 1564 
2 RFs 1371 856 934 
3 RFs 455 604 189 
4 RFs 85 97 13 
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HRs for MACE accrording to PR within each risk level. 
20µΜ ADP 
   0 - 40   41 - 60   61 - 100 
Risk 
level HR HR [95%CI] p value HR [95%CI] p value 
No RF 1 (ref) 0.96 [0.33;2.79] 0.95 2.15 [0.68;6.82] 0.19 
1 RF 1 (ref) 1.20 [0.66;2.18] 0.55 3.19 [1.59;6.41] 0.001 
2 RFs 1 (ref) 2.91 [1.42;5.97] 0.004 3.87 [1.70;8.81] 0.001 
3, 4 RFs 1 (ref) 2.99 [1.12;7.97] 0.03 3.31 [1.15;9.54] 0.03 
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Supplemental Table 1. Sensitivity analysis for the association between PR using 20 µM ADP and risk of MACE (leave-one-
out procedure) 
 
 
 20 µM ADP LTA 41%–60% 20 µM ADP LTA 61%–100% 
Interaction between PR 
and risk level 
 
Removed study N analysed / N events HR [95% CI] p HR [95% CI] p p 
Hochholzer et al. 3375/267 1.98 [1.29;3.04] 0.002 3.29 [2.00;5.43] <0.0001 0.08 
Reny et al. 3637/235 1.91 [1.25;2.92] 0.003 3.19 [1.86;5.47] <0.0001 0.22 
Angiolillo et al. 3967/251 2.04 [1.35;3.10] 0.0008 2.93 [1.74;4.94] <0.0001 0.02 
Campo et al. 4075/283 1.77 [1.20;2.62] 0.004 2.57 [1.60;4.12] <0.0001 0.04 
Cuisset et al. 2007 3951/279 1.81 [1.23;2.67] 0.003 2.81 [1.67;4.73] <0.0001 0.08 
Geisler et al. 3191/259 1.97 [1.28;3.05] 0.002 3.20 [1.81;5.68] <0.0001 0.04 
Gurbel et al. 3882/252 1.61 [1.07;2.41] 0.02 2.31 [1.46;3.66] 0.0004 0.08 
Breet et al. 3089/197 1.75 [1.15;2.67] 0.009 2.89 [1.61;5.18] 0.0004 0.03 
Yong et al. 3953/273 1.84 [1.24;2.75] 0.003 3.06 [1.85;5.06] <0.0001 0.07 
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Supplemental Table 2. Results of the sensitivity analysis for the modification of the association between PR, assessed 
with 20 µM ADP and risk of MACE 
 
Reny study removed Geisler study removed Campo study removed 
Geisler & Campo  
studies removed Angiolillo study removed 
HR [95% CI] p HR [95% CI] p HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Interaction with  
Nb Risk factors 
   No risk factors 
     ADP 20 0%-40% Ref Ref Ref Ref Ref 
     ADP 20 41%-60% 1.26 [0.31;5.03] 0.75 0.94 [0.32;2.71] 0.90 0.96 [0.33;2.78] 0.95 0.93 [0.32;2.69] 0.90 0.96 [0.33;2..78] 0.94 
     ADP 20 61%-100% 2.23 [0.50;9.72] 0.29 2.05 [0.60;6.93] 0.25 1.88 [0.61;5.77] 0.27 1.68 [0.52;5.36] 0.38 1.98 [0.62;6.35] 0.25 
   One risk factor 
     ADP 20 0%-40% Ref Ref Ref Ref Ref 
     ADP 20 41%-60% 1.43 [0.74;2.77] 0.28 1.45 [0.75;2.83] 0.27 1.16 [0.64;2.11] 0.62 1.40 [0.72;2.72] 0.33 1.47 [1.01;2.14] 0.54 
     ADP 20 61%-100% 4.03 [1.89;8.63] 0.0003 4.24 [1.85;9.69] 0.0006 2.77 [1..44;5.31] 0.002 3.43 [1.63;7.24] 0.001 3.02 [1.45;6.26] 0.003 
  Two or more risk  
factors 
     ADP 20 0%-40% Ref Ref Ref Ref Ref 
     ADP 20 41%-60% 2.47 [1.36;4.49] 0.003 3.04 [1.54;6.00] 0.001 2.82 [1.55;5.13] 0.0007 2.96 [1.46;6.00] 0.003 3.85 [1.95;7.58] <0.0001 
     ADP 20 61%-100% 3.54 [1.71;7.31] 0.0006 4.01 [1.71;9.38] 0.001 3.15 [1.60;6.19] 0.0009 3.20 [1.43;7.14] 0.005 4.47 [1.97;10.16] 0.0003 
    Interaction (p) 0.22   0.04   0.04   0.04   0.02 
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Supplemental Table 3. Results of the sensitivity analysis for the modification of the association between PR using 20 µM 
ADP and risk of MACE in patients with PCI at inclusion and when target vessel revascularisation (TVR) is 
included in the composite outcome of MACE.  
 
  Patients with PCI MACE event definition incl. TVR 
N patients 3,406 1,066 
N events 198 160 
HR [95% CI]  p HR [95% CI] p 
Interaction with      
Nb Risk factors 
   No risk factors 
       ADP 20 0%-40% Ref Ref 
       ADP 20 41%-60% 1.26 [0.31;5.04] 0.75 1.43 [0.69;5.04] 0.58 
       ADP 20 61%-100% 2.32 [0.51;10.49] 0.27 3.41 [0.67;17.41] 0.14 
   One risk factor 
       ADP 20 0%-40% Ref Ref 
       ADP 20 41%-60% 1.44 [0.72;2.89] 0.3 2.24 [0.73;6.89] 0.16 
       ADP 20 61%-100% 4.16 [1.78;9.72] 0.001 7.52 [1.86;30.37] 0.005 
  Two or more risk  factors 
       ADP 20 0%-40% Ref Ref 
       ADP 20 41%-60% 3.36 [1.61;6.8] 0.001 4.07 [1.79;9.28] 0.0008 
       ADP 20 61%-100% 4.97 [2.03;12.16] 0.0004 6.14 [1.82;20.65] 0.003 
    Interaction (p)   0.21   0.25 
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Supplemental Figure 4. Funnel plot for detection of a potential publication bias.  
The hazard ratio for the association between PR using 20 µM ADP (per 10%) and the risk of 
MACE was assessed in each study with adjustment on risk factors. The logarithm of the 
hazard ratios and their standard errors were represented in the funnel plot (white circles). 
The white diamond shows the pooled hazard ratio (1.25, 95% CI 1.08 to 1.44). Two studies 
were detected as missing using the ‘trim and fill’ method for the funnel plot to be symmetrical 
(black circles). However, when these missing studies were added, the pooled hazard ratio 
was not significantly modified (1.21, 95% CI 1.05 to 1.40). 
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